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ABSTRACT OF THE DISSERTATION
Dissecting the Role and Regulation of Transcription Factor Zeb2 in Hematopoiesis
by
Xiao Huang
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2021
Professor Kenneth M. Murphy, Thesis Advisor
A potent immune response requires crosstalk and collaboration between the innate and
adaptive immune systems, both of which contain highly specialized immune lineages. All
immune lineages arise during adult life are generated from the differentiation of hematopoietic
stem cells (HSCs) in the process of hematopoiesis. Normal hematopoiesis under steady state and
emergency hematopoiesis during immune response are orchestrated precisely by transcriptional
networks formed by transcription factors (TFs) to direct multipotent progenitors into specific
fate. TFs required for the development of single or multiple lineages within the hematopoietic
system has been identified, such as Irf8 for type I classical dendritic cells (cDC1s), Id2 and Nfil3
for innate lymphoid cells (ILCs), and Zeb2 for plasmacytoid dendritic cells (pDCs) and
monocytes, however, how these TFs interact with each other to enforce lineage fate choices and
what cis-element in their genomic locus are employed to execute such interactions and thus form
regulatory networks were poorly defined.
In the first part of this dissertation, we dissected the transcriptional networks involving
TF Zeb2 in the fate choice of common dendritic cell progenitors (CDPs) between pDC and
cDC1s. Using sc-RNA seq and several reporter mouse lines for relevant transcription factors, we
ix

identified the earliest type 1 conventional DC (cDC1) specified cells as a fraction of common
dendritic cell progenitors (CDPs) marked by low expression of transcription factor Zeb2 and
high expression of transcription factor Id2. We also defined a regulatory network of
transcription factors involving Nfil3, Zeb2, and Id2 that controls the specification of the CDPs
into a clonogenic progenitor for the cDC1 lineage. This network also imposes a switching in the
usage of Irf8 enhancer.
In the second part of this dissertation, we examined the molecular mechanisms governing
the expression of Zeb2 across hematopoietic system, specifically how such regulation differs
between fetal and adult animals. Using ATAC-seq and ChIP-seq analysis, we identified a ciselement 165kb upstream of Zeb2 transcription starting site (TSS) (-165kb Zeb2 enhancer). We
generated a novel mouse model deficient in this enhancer and detected impaired Zeb2 expression
throughout the hematopoietic system. We demonstrated that this enhancer and subsequently
Zeb2 expression is required for the development of pDC, monocytes and B cells, the terminal
maturation of NK cells under steady state, and CD8+ T cell terminal differentiation in response to
acute murine LCMV infection. Surprisingly, the -165-kb Zeb2 enhancer is not required for Zeb2
expression in embryonically derived macrophage populations and their embryonic progenitors.
Employing scATAC-seq technique we were able to demonstrate that the fetal-derived
macrophage lineages utilize an alternative enhancer to drive Zeb2 expression. This enhancer,
164-kb downstream of Zeb2 TSS (+164-kb Zeb2 enhancer) is likely bound by TF Nur77. These
discoveries provided novel insights into the precise regulation of TF expression and interactions
during embryonic development and hematopoiesis.

x

CHAPTER 1:
Introduction to Transcription factor Zeb2 and hematopoiesis

Parts of this chapter were published in Annual Reviews of Cell Development and Biology.
Bagadia, P., Huang, X., Liu, T., and Murphy KM. Shared Transcriptional Control of Innate
Lymphoid Cell and Dendritic Cell Development. Annual Review of Cell and Developmental
Biology 35, 381-406 (2019).
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1.1

Abstract
Hematopoiesis is the process of generating the entire hematopoietic systems from

multipotent progenitor cells. The complex networks of transcription factors (TFs) enforce precise
and timely decisions between fates and ensure the homeostasis of different immune lineages. In
this chapter, we discuss the key findings of hematopoiesis with a special focus on the dendritic
cell (DC) lineages. We also review the recent discoveries regarding the TF Zeb2 and its functions
in immune cell development.

1.2

Hematopoiesis and immune responses
Mammalian hematopoiesis occurs in three phases. Primitive hematopoiesis begins in the

yolk sac (YS) around embryonic age 7.0 (E7.0), producing nucleated erythrocytes and
macrophages (MFs)1. Transient definitive hematopoiesis begins in the YS around E8.5,
producing erythro-myeloid progenitors (EMPs) and lympho-myeloid progenitors 2-4. Finally,
definitive hematopoiesis begins when hematopoietic stem cells (HSCs) colonize the fetal liver
(FL) around E10.5 and persists in the bone marrow throughout adult life to generate lineages
belonging to both the adaptive and innate immune system.
A strong immune response against pathogens requires interactions and communications
between the innate and adaptive immune systems. The two systems are composed of highly
specialized immune lineages. Innate immune responses involve many different types of innate
cells, such as neutrophils, monocytes, and specifically discussed in this chapter, innate lymphoid
cells (ILCs) and dendritic cells (DCs). Innate cells recognize pathogens through their germlineencoded receptors and are the first to initiate proinflammatory responses aiming to contain and
rapidly clear an infection. Importantly, innate cells direct the specific type of adaptive immune
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response most effective at clearing a particular type of infection via secretion of cytokines and
chemokines. The adaptive immune response can be divided into three types of immunity,
specific to the type of pathogen that evokes the response. Type I immunity is directed towards
intracellular pathogens, such as bacteria and viruses, while type II immunity protects against
helminthes and environmental substances. Type III immunity is involved in protection against
extracellular bacteria and fungi. Each of these immune responses corresponds to a specific type
of T cell expressing antigen-specific receptors, and specific innate cells, ILCs and DCs, that
together effectively responds to pathogen invasion.
ILCs are often considered innate T cells, as they share functional and developmental
similarities. Like T cells, ILCs can be divided into several distinct subsets that correspond to
each of the three types of immunity previously discussed. However, unlike T cells, which have
antigen-specific receptors, undergo clonal selection, and expand when stimulated, ILCs do not
have antigen-specific receptors or the ability to undergo clonal selection. Instead, they rapidly
respond to the pathogen and secrete cytokines to control the infection. Their developmental
similarities have been discussed in detail in other reviews, and will not be discussed extensively
in this chapter5,6.
DCs are characterized as professional antigen presenting cells responsible for priming T
cells for potent T cell activation. DCs encode a number of receptors that allow for antigen
uptake, antigen processing, and antigen presentation to MHC molecules on T cells. Initially
thought of as one family, DCs are now recognized for their heterogeneity in both location and
function, with distinct subsets specialized for specific response. Two sets of
classical/conventional DCs (cDCs), cDC1 and cDC2, as well as plasmacytoid DCs (pDCs) and
epidermal Langerhans cells (LCs) have been identified7-10.

3

1.3

DC development
DC development can be divided into three distinct stages and relies on some of the

transcription factors that are also required for the development of other lineages.
Stage 1 begins with the specification of dendritic cell precursors from common myeloid
progenitor (CMP)that are multipotent for myeloid potential to monocyte-dendritic cell
progenitors (MDP) that are multipotent for macrophage and dendritic cell potentials, and finally
to common dendritic cell progenitors (CDP) that retain only dendritic cell potential. DCs
comprise three subsets – pDCs, cDC1, and cDC2 – and the CDP gives rise to all three subsets.
Stage 2 is defined by the commitment of specified progenitor to specific DC subsets. Previous
work has defined progenitors committed to either cDC1 or cDC2 fate, and recent work has aimed
to elucidate a progenitor that is committed to pDC fate. Stage 3 is the maintenance of DCs in
peripheral tissues. Stage 1 is the specification of multipotent progenitors that have lymphoid,
granulocyte and myeloid potentials to progenitors that retain only dendritic cell potential. Early
progenitors that can give rise to DCs in vivo are the CMP and the LMPP11-14. The next progenitor
thought to arise from the CMP and still retain dendritic cell potential is the
granulocyte/macrophage progenitor (GMP), but recent studies have shown that the GMP cannot
develop into dendritic cells15. The macrophage/dendritic cell progenitor (MDP) arises from the
CMP and only produces macrophages and dendritic cells both in vitro and in vivo15-18. The exact
transcriptional mechanisms that cause the divergence and the exclusion from neutrophil fate
between these progenitors are not currently known. However, the transcription factors PU.1,
IRF8, and members of the CEBP family are thought to influence the development of these cell
lineages. The MDP is thought to give rise to the CDP, but the exact developmental mechanisms,
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including how macrophage potential is excluded, remain unclear. The LMPP can give rise to
other lymphoid progenitors, such as the CLP, which has the potential to give rise to pDCs19-21.
pDCs have been thought to arise also from lymphoid cells, as they can be traced with IL7R, and
recent work has shown that the majority of pDCs come from the CLP rather than the CDP21.
Stage 2 of DC development is the commitment of the CDP to clonogenic progenitors that
give rise to cDC1s, cDC2s, or pDCs. Clonogenic progenitors for cDC1s and cDC2s, namely precDC1s and pre-cDC2s, were identified in 201522,23, and a progenitor for pDCs was elucidated in
201821. Many transcription factors have been identified as important factors for cDC1, cDC2,
and pDC development, and recent work has identified how transcription factors interact in the
cDC1 lineage.
cDC1 development depends on expression of the transcription factors IRF8, BATF3,
NFIL3, and ID2 and suppression of the transcription factor ZEB222,24-29. IRF8 is a lineagedefining factor for cDC1 and Irf8-/- lack CDPs, pre-cDC1s, and cDC1s. Progenitors deficient in
IRF8 diverted toward the granulocyte lineage and produced more neutrophils, indicating a role
for IRF8 in regulating myeloid/granulocyte potential30. BATF3, a transcription factor belonging
to the Batf family, has a leucine zipper domain that heterodimerizes with JUN and IRF factors31.
Studies aiming to understand the relationship between IRF8 and BATF3 began in 2015 whenprecDC1 population was identified as a Lineage-CD117intCD135+MHC-IIlow-intCD11c+SiglecHcells that are either CD24+ or Zbtb46gfp+22. ZBTB46, a transcription factor belonging to the
Broad Complex, Tramtrack, Bric-a-Brac, and Zinc Finger family, is selectively expressed in
cDCs and their progenitors, but is not required for their development32,33. Pre-cDC1s are present
in Batf3-/- mice, but not Irf8-/- mice, indicating that specification of the pre-cDC1s could occur in
the absence of BATF3. Batf3-/- pre-cDC1 fail to maintain IRF8 expression, resulting in
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divergence to the cDC2 lineage22. High expression of IRF8 is necessary for the cDC1 lineage,
and it was discovered that BATF3 is required to maintain IRF8 autoactivation following
specification to cDC1 fate147. ChIP-seq analysis identified a +32 kb Irf8 enhancer containing
several AP1-IRF composite elements (AICEs) that binds IRF8 and BATF3 in cDC1s in vivo.
Recently, CRISPR-mediated deletion of the +32 kb Irf8 enhancer in mice (Irf8 +32–/–) suggests
that BATF3 supports Irf8 autoactivation using this enhancer. Like Batf3–/– mice, Irf8 +32–/– mice
lack mature cDC1 but maintain pre-cDC1 development in vivo. Development of this progenitor
instead depends upon a +41 kb Irf8 enhancer, which binds E proteins and is active in mature
pDCs and cDC1 progenitors, but not mature cDC1s. Deletion of this enhancer eliminated Irf8
expression in pDCs and also completely eliminated development of the specified pre-cDC1. This
enhancer activity requires E proteins to induce sufficient levels of IRF8 during specification of
the pre-cDC1, but it is still unclear why mature cDC1s require BATF3 and the +32 kb Irf8
enhancer to maintain Irf8 expression.
Recent work from our lab has organized the transcription factors NFIL3, ID2, and ZEB2
into a transcriptional network that governs cDC1 fate34. NFIL3, a basic leucine zipper (bZIP)
transcriptional repressor35,36, is expressed in, and required for cDC1, but not cDC2 or pDC,
development37,38. ID2 is a known inhibitor of E proteins and is expressed in cDC1 and cDC2, but
not in pDCs, and is required only for cDC1 development39,40. Current models propose that ID2
excludes the pDC fate in DC progenitors by blocking activity of E proteins, particularly E2-2
(Tcf4), required for pDCs41-43. The transcriptional repressor ZEB2 is expressed in pDCs and
cDC2s, but not cDC1s. It acts to suppress cDC1 development and is required for pDC
development, perhaps through inhibition of Id2 transcription28,29.
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We found that the CDP originates in a Zeb2hi and Id2lo state in which IRF8 expression is
maintained by the +41 kb Irf8 enhancer. Single-cell RNA-sequencing of the CDP identified a
fraction of the CDP that is already specified to cDC1 fate, in a stage earlier than the pre-cDC1.
This fraction already expressed ID2, BATF3, and ZBTB46, and excludes ZEB2. This fraction’s
development arises when NFIL3 induces a transition into a Zeb2lo and Id2hi state. A circuit of
mutual Zeb2-Id2 repression serves to stabilize states before and after this transition. ID2
expression in the specified pre-cDC1 inhibits E proteins, blocking activity of the +41 kb Irf8
enhancer, and thereby imposing a new requirement for BATF3 for maintaining Irf8 expression
via the +32 kb Irf8 enhancer34.
Transcriptional mechanisms governing cDC2 and pDC development are less known, but
progenitors for each lineage have been identified. Pre-cDC2s were identified in 2015 as a
Lineage-CD117lowCD135+CD115+MHC-II-CD11c+Zbtb46gfp+ cells in the BM147. Although the
pre-cDC2s expresses IRF8, mature cDC2 only express IRF4. However, Irf4-/- mice do not lack
cDC2, although the cDC2s that develop exhibit defective migration44. As discussed earlier in the
review, two transcription factors, KLF4 and NOTCH2, have selectively ablated specific cDC2
populations, but how heterogeneity in the cDC2 lineage develop and it specification to distinct
cDC2 population remains unclear. Additionally, the mechanism behind pre-cDC2 losing IRF8 to
become IRF4-dependent is also unknown.
pDC development depends on the transcription factors TCF4, ZEB2, and
BCL11A29,41,45,46. pDCs also express high levels of IRF8, but are present in Irf8-/- mice with
altered phenotype and functionality26. The basis for lineage divergence between pDCs and cDCs
from the CDP is not known, but analysis of the +41 kb Irf8 enhancer might suggest that a shared
progenitor between pDCs and cDC1s exist. Alternatively, a pDCs might arise completely
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separately from the CLP, as has been suggested in a recent work that identified a pre-pDC21. This
study characterized a pre-pDC as a
Lin−CD16/32−B220−Ly6C−CD117int/loCD135+CD115−CD127+SiglecH+Ly6D+ cell21. PrepDCs express high levels of IRF8 and once matured, express TCF4.
Stage 3 of DC development concerns its maintenance and regulation in peripheral tissues.
Studies have suggested that cytokines and some transcription factors are required for control of
DC populations and may regulate DC plasticity in tissues.

1.4

Zeb2 and its role in hematopoiesis
ZEB2 is a zinc-finger transcriptional repressor that was first shown to be a regulator of

epithelial-mesenchymal transition (EMT) via interaction with Smad family proteins47-50. ZEB2
has two clusters of zinc fingers for DNA binding, one at each terminus. Both clusters can bind to
E boxes or CACCT sequence and are necessary for repression48,49. ZEB2 can exert its repressive
function by directly interacting with C-terminal binding proteins (CtBP), a known co-repressor
family, via its CtBP interaction domain (CID). Most notably, ZEB2 is a known partner of Smad
family proteins and can bind with Smad 1, 2, 3, 5, and 8, known as R-smads50. Germline deletion
of Zeb2 leads to embryonic lethality in mice51,52. ZEB2 performs a wide range of functions in
multiple systems, ranging from dysregulation in several types of cancer53 to modulating
myelination of oligodendrocytes54. In 2011, the role of ZEB2 in the hematopoietic system was
first demonstrated, as Zeb2 deletion using Tie-2-cre or Vav-cre results in defect in HSC
differentiation and homing to bone marrow55.
ZEB2 is required for NK cell terminal maturation, as shown with a NK cell-specific
deletion of Zeb2 (Ncr1icre)56. NK cell-specific Zeb2 deletion results in reduced survival for
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mature NK cells, defect in their exit from BM, and increased susceptibility to B16F10
melanomas56. TBX21 has been shown to be necessary and sufficient to induce ZEB2 expression
in NK cells, and Zeb2-deficient mature NK cells phenocopies their Tbx21-deficient counterparts.
Several studies had associated ZEB2 with T cell terminal differentiation and memory
formation. In response to LCMV infection, ZEB2 is upregulated by KLRG1hi effector CD8+ T
cells, and loss of Zeb2 expression in these cells results in the loss of antigen-specific CD8+
effector cells and the impairment of generation of effector memory cells, while the formation of
central memory T cells was accelerated57,58. Later studies further demonstrate that coordinated
expression of Zeb2 and its family member, Zeb1, is critical for CD8+ T cell fate decision. ZEB2
promoted terminal T cell differentiation, whereas ZEB1 was critical for memory T cell survival
and function, with the TGF-b signaling selectively induce Zeb1 and repress Zeb259.
Within the DC compartment, ZEB2 was shown to be required for pDC development28,29.
One study suggests that ZEB2 is also required for cDC2 development28, while another indicated
that ZEB2 is dispensable for cDC2 development and is instead required to actively repress
generation of cDC1 progenitors29. Our recent work shows that ZEB2 forms a mutually repressive
loop with ID2 and is repressed by NFIL3 in the CDP to allow overall expression of Id2 for cDC1
specification. The mechanisms by which Zeb2 influences ILC and DC lineage fates are less clear
than the mechanisms by which Id2 and Nfil3 might influence fate and requires further
investigation.

1.5

Conclusions
Major questions remain regarding the target, as well as regulators of Zeb2 in

hematopoiesis. It is clear that ZEB2 plays an important role in lineage bifurcations at multiple
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stages during hematopoiesis, and mechanisms governing the expression of Zeb2 and its
downstream targets might be shared among hematopoietic progenitors to resolve fate decisions.
In this dissertation, we attempt to first use DCs as a model lineage to interrogate the
interactions between Zeb2 and other TFs that are required for the development of said lineages;
and additionally, examine the molecular mechanisms regulating the expression of Zeb2 across
the entire hematopoietic tree, spanning from embryonic development to adulthood. The result
from this dissertation may provide more insight into the modality of TF regulation in the
development.
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CHAPTER 2:
An Nfil3–Zeb2–Id2 pathway imposes Irf8 enhancer switching during cDC1 development
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2.1

Abstract
Classical type 1 dendritic cells (cDC1s) are required for anti-viral and anti-tumor

immunity, which necessitates an understanding of their development. Development of the cDC1
progenitor requires an E protein–dependent enhancer located 41 kilobases downstream of the
transcription start site of the transcription factor IRF8 (+41 kb Irf8 enhancer), but its maturation
instead requires the BATF3-dependent +32 kb Irf8 enhancer. To understand this switch, we
performed single-cell RNA sequencing of the common dendritic cell progenitor (CDP) and
identified a cluster of cells that expressed transcription factors that influence cDC1 development,
such as Nfil3, Id2, and Zeb2. Genetic epistasis among these factors revealed that Nfil3 expression
is required for the transition from Zeb2hi and Id2lo CDPs to Zeb2lo and Id2hi CDPs, which
represent the earliest committed cDC1 progenitors. This genetic circuit blocks E protein activity
to exclude plasmacytoid DC potential and explains the switch in Irf8 enhancer usage during
cDC1 development.

2.2

Introduction
Development of classical type 1 dendritic cells (cDC1s) has become a topic of interest

because of the critical role this lineage plays in anti-tumor immunity and checkpoint blockade
therapy1. DCs are an immune lineage encompassing classical DCs (cDCs) and plasmacytoid
DCs (pDCs)2,3. cDCs comprise two branches, cDC1 and cDC2, that exert distinct functions in
vivo and rely on different transcriptional programs4. pDCs and cDCs can both arise from the
common DC progenitor (CDP)5-7. cDC progenitors (pre-cDCs) include clonogenic populations
separately committed to cDC1 or cDC2 lineages8,9. Similar progenitors have been confirmed in
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human DC development10-12. However, the precise transcriptional programs underlying DC
specification and commitment remain unclear.
The transcription factors Irf8 and Batf3 are required for cDC1 development9,13,14, but
cDC1 develop from CDP progenitors that express Irf8 independently of Batf3, yet later become
dependent on Batf3 to maintain Irf8 expression. The basis for this switch from Batf3independent to Batf3-dependent Irf8 expression is unclear. A clonogenic cDC1 progenitor, the
pre-cDC1, develops normally in Batf3–/– bone marrow (BM) but fails to maintain Irf8
expression9, causing it to divert into cells that are transcriptionally similar to cDC2. An enhancer
located at +32 kb of the Irf8 transcription start site contained several AP1-IRF composite
elements (AICEs) that bind IRF8 and BATF3 in cDC1s in vivo9. CRISPR-mediated deletion of
the +32 kb Irf8 enhancer in mice (Irf8 +32–/–) suggests that BATF3 supports Irf8 autoactivation
using this enhancer. Like Batf3–/– mice, Irf8 +32–/– mice lack mature cDC1 but maintain precDC1 development in vivo. Development of this progenitor instead depends upon a +41 kb Irf8
enhancer, which binds E proteins and is active in mature pDCs and cDC1 progenitors, but not
mature cDC1s. In vivo deletion of this enhancer eliminated Irf8 expression in pDCs and also
completely eliminated development of the specified pre-cDC1. This enhancer activity requires E
proteins to induce sufficient levels of IRF8 during specification of the pre-cDC1, but it is still
unclear why mature cDC1s require BATF3 and the +32 kb Irf8 enhancer to maintain Irf8
expression.
Other transcription factors are known to influence cDC1 development, such as Nfil3, Id2,
and Zeb215-19. Nfil3, a basic leucine zipper (bZIP) transcriptional repressor20, is expressed in
cDC1s and is required for cDC1 development15,21, but its mechanism of function is unknown4,15.
Id2, a known inhibitor of E proteins, is expressed in both cDC1 and cDC2, and is required only
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for cDC1 development16,17. Id2 may exclude pDC fate by blocking activity of E proteins,
particularly E2-2 (Tcf4), required for pDCs22-24. However, this model predicts that Id2–/– mice
should lack both cDC1 and cDC2 lineages, since both lineages must exclude pDC fate. Finally,
the transcriptional repressor Zeb2 is required for pDC development and suppresses cDC1
development, perhaps through inhibition of Id2 transcription18,19. The exact mechanisms by
which these factors interact and how it influence cDC1 specification is unknown.
Here, we used single-cell RNA-sequencing and genetic epistasis to determine the
functional hierarchy of transcription factors involved in cDC1 specification. We organized a
transcriptional circuit that explains the switch in Irf8 expression from being Batf3-independent to
being Batf3-dependent. The CDP originates in a Zeb2hi and Id2lo state in which Irf8 expression
is maintained by the +41 kb Irf8 enhancer. Single-cell RNA-sequencing identified a fraction of
the CDP that exclusively possesses cDC1 fate potential. This fraction’s development arises when
Nfil3 induces a transition into a Zeb2lo and Id2hi state. A circuit of mutual Zeb2-Id2 repression
serves to stabilize states before and after this transition. Id2 expression in the specified pre-cDC1
inhibits E proteins, blocking activity of the +41 kb Irf8 enhancer, and thereby imposing a new
requirement for Batf3 for maintaining Irf8 expression via the +32 kb Irf8 enhancer.

2.3

Results

The earliest committed cDC1 progenitor arises within the CDP
The CDP was originally defined as a Lin–CD117intCD135+CD115+ BM population and
was observed to be, although not defined as, largely negative for MHC-II and CD11c
expression6. Subsequently, pre-cDC1 and pre-cDC2 progenitors were identified to arise from the
CDP but were not contained within the CDP8,9. Pre-cDC1s were defined as Lin–
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CD117intCD135+CD11c+MHC-IIlo-int and were largely CD115–. They can be defined using two
methods, relying either on Zbtb46-GFP expression in Zbtb46gfp/+ reporter mice, or on
conventional surface markers (Figure 2.1a)9,25. In each case, we noticed that approximately 10%
of pre-cDC1s expressed CD115. The expression of CD115 in the pre-cDC1 suggested that cDC1
specification could occur at an earlier developmental stage in the CDP. In agreement, 5-10% of
CDPs, defined on the strict exclusion of CD11c- and MHC-II- expressing cells, are Zbtb46GFPpos (Figure 2.1b). These Zbtb46-GFPpos CDPs had nearly exclusive cDC1 potential in vitro,
comparable to pre-cDC1, and completely lacked pDC and cDC2 potential. This was in contrast
to the Zbtb46-GFPneg CDPs, which produced cells from all three DC lineages (Figure 2.1c,
Figure 2.3a).
The transcriptional profile of these Zbtb46-GFPpos CDPs suggests they represent an
intermediate population between a non-specified CDP, the Zbtb46-GFPneg CDP, and the precDC1 (Figure 2.1d,e). For example, we considered genes whose expression changed more than
8-fold between the Zbtb46-GFPneg CDP and the pre-cDC1. For such genes, their expression in
Zbtb46-GFPpos CDPs was consistently intermediate between their expression in Zbtb46-GFPneg
CDPs and pre-cDC1s (Figure 2.1d,e). Id2 expression in Zbtb46-GFPneg CDPs was increased by
34-fold in pre-cDC1s, but only by 15-fold in Zbtb46-GFPpos CDPs. Likewise, Zeb2 expression
in Zbtb46-GFPneg CDPs was reduced by 9-fold in pre-cDC1s, but only by 3.6-fold in Zbtb46GFPpos CDPs. As expected, the Zbtb46-GFPpos CDPs were segregated away from the pre-cDC2
(Figure 2.1e). Thus, these results indicate that Zbtb46-GFPpos CDPs are an earlier and distinct
stage of cDC1 specification compared with the more abundant pre-cDC1 described previously.
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Single-cell RNA-sequencing of the CDP identifies factors associated with cDC1
specification
The identification of Zbtb46-GFP expressing cells in the CDP that had nearly exclusive
cDC1 potential suggested that the CDP might contain cells that have already specified to cDC1
fate. Single-cell RNA-sequencing (scRNA-seq) was performed on 9,554 CDPs defined as Lin–
CD127–CD117intCD115+CD135+MHC-II–CD11c– (Figure 2.2a) on the 10X Genomics platform
to assay for unrecognized heterogeneity within this population. Uniform Manifold
Approximation and Projection (UMAP) analysis26-28 identified 8 closely connected clusters
(Figure 2.2b,c). Although we were able to identify genes that were specifically enriched in
certain clusters, others such as Klf4 and Ly6d were not specifically enriched in one cluster
(Supplementary Figure 2.3b). However, scRNA-seq was able to identify a cluster that was
enriched in Zbtb46 expression, corroborating our data above with the Zbtb46-GFP reporter mice.
Zbtb46 was expressed in cluster 3, which also showed restricted expression of Id2 and Batf3, but
excluded expression of Tcf4 (E2-2) and Zeb2 (Figure 2.2d,e). Cluster 3 also showed reduced
Csf1r expression (Figure 2.2d), consistent with lower CD115 expression in pre-cDC1 and
incongruent with the higher CD115 expression in the bulk CDP (Figure 2.1a). As expected, Flt3
and Irf8 were uniformly and highly expressed (Figure 2.2d, e). Cluster 7, the only other Tcf4
negative cluster, likely contained macrophage or neutrophil contamination as this cluster
expressed Ccl6 and did not contain many cells (Figure 2.2c,d). Other factors impacting DC
development such as Bcl11a, Spi1, Klf4, and Notch229,30,31,32 were not differentially expressed
across the CDP, perhaps suggesting that specification of cDC2s and pDCs occurs after the CDP
(Figure 2.2d, Figure 2.3b). In addition, the CDP appeared homogenous with respect to markers
of proliferation (Figure 2.2f). Thus, scRNA-seq identifies a cluster of cells within the CDP that
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coordinately induces Nfil3, Id2, Batf3 and Zbtb46, and reduces Tcf4 and Zeb2, suggesting these
genes may regulate cDC1 specification at an earlier stage than previously recognized.

cDC1 specification is functionally characterized by low Zeb2 and high Id2 expression
To test the functional importance of these genes for cDC1 specification, we first analyzed
two reporter mouse lines expressing a ZEB2-EGFP fusion protein (Zeb2egfp)33 or an Id2-IRESGFP cassette (Id2gfp)34. Both reporters exhibit a GFP expression pattern consistent with the level
of Zeb2 and Id2 gene expression across many immune lineages (Figure 2.5a,b). In Zeb2egfp mice,
90% of CDPs expressed high levels of ZEB2-EGFP, but 10% expressed low levels of ZEB2EGFP, similar to low levels of ZEB2-EGFP expressed by pre-cDC1s (Figure 2.4a). In Id2gfp
mice, 94% of CDPs expressed low Id2-GFP, but 6% expressed high levels of Id2-GFP similar to
the high levels of Id2-GFP expressed by pre-cDC1s (Figure 2.4b). Thus, both Zeb2egfp and Id2gfp
reporter lines confirm the existence of ZEB2-EGFPlo and Id2-GFPhi cells within the CDP as
predicted by scRNA-seq.
We next analyzed the developmental potential of CDPs expressing high or low levels of
ZEB2-EGFP, Id2-GFP, and Zbtb46-GFP in an in vitro Flt3L culture system. CDPs expressing
low levels of ZEB2-EGFP showed significantly increased cDC1 potential (66%) compared with
CDPs expressing high levels of ZEB2-EGFP (26%) (Figure 2.4c,e). Likewise, CDPs expressing
high levels of Id2-GFP showed significantly increased cDC1 potential (77%) compared with
CDPs expressing low levels of Id2-GFP (30%) at both days 5 and 7 of in vitro Flt3L culture
(Figure 2.4d,e, Figure 2.5c,d). Finally, CDPs expressing Zbtb46-GFP developed nearly
exclusively into cDC1 (96%), while CDPs lacking Zbtb46-GFP developed into both cDC1 (30%)
and cDC2 (70%) (Figure 2.1c, 2.4e). In all three cases, pDCs developed exclusively from CDPs
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that were either Zbtb46-GFPneg, ZEB2-EGFPhi, or Id2-GFPlo (Figure 2.5e-j). These results
suggest that CDPs expressing low levels of Zeb2-EGFP or high levels of Id2-GFP are biased
toward cDC1 development, but not as completely as CDPs expressing Zbtb46-GFP.
The transcriptional profile of CDPs expressing low levels of ZEB2-EGFP or high levels
of Id2-GFP suggests that these cells are an intermediate population between non-specified CDPs
and the pre-cDC1 (Figure 2.4f-i). We considered genes whose expression differed more than 5fold between the pre-cDC1 and either ZEB2-EGFPhi CDPs (Figure 2.4f,g) or Id2-GFPlo CDPs
(Figure 2.4h,i). The expression of such genes in ZEB2-EGFPlo CDPs was consistently
intermediate between the expression in ZEB2-EGFPhi CDPs and pre-cDC1s (Figure 2.4f,g).
Likewise, the expression of such genes in Id2-GFPhi CDPs was consistently intermediate
between the expression in Id2-GFPlo CDPs and pre-cDC1s (Figure 2.4h,i). Additionally, the
cells that are ZEB2-EGFPlo within the CDP have induced Id2, and cells that are Id2-GFPhi within
the CDP have downregulated Zeb2 (Figure 2.4f-i). Both of these populations also show
increasing Zbtb46 expression compared to the non-specified CDPs. Although these three cDC1specificed CDP populations differ in cDC1 potential, their transcriptional profiles suggest that
they are highly overlapping. In summary, CDPs that express low ZEB2-EGFP or high Id2-GFP
represent an earlier stage of cDC1 specification compared to the previously identified pre-cDC1.

Nfil3 is required for cDC1 specification within the CDP
Nfil3 is required for cDC1 development15, but its mechanism and timing of action remain
obscure. To determine the stage where Nfil3 acts in cDC1 development, we crossed Nfil3–/– mice
with ZEB2-EGFP, Id2-GFP and Zbtb46-GFP reporter mice, and assayed whether cDC1specified progenitors developed in BM. In Nfil3+/+Zbtb46gfp/+ reporter mice, cDC1-specified
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cells can be identified as CD117intZbtb46-GFPpos cells that include pre-cDC1s and Zbtb46GFPpos CDPs and comprise approximately 5% of Lin–CD135+ BM (Figure 2.6a,b). However,
these cells are absent in Nfil3–/–Zbtb46gfp/+ mice, but do develop normally in Batf3–/–Zbtb46gfp/+
mice as previously described (Figure 2.7a)9. Within the CDP, cDC1-specified cells can be
identified as Zbtb46-GFPpos cells that comprise 5% of the CDP (Figure 2.6a,b). However, these
cells are also absent in Nfil3–/–Zbtb46gfp/+ mice.
In Nfil3+/+Zeb2egfp reporter mice, cDC1-specified cells are identified as CD117int ZEB2EGFP lo cells that includes pre-cDC1s and ZEB2-EGFPlo CDPs and comprise approximately 6%
of Lin–CD135+ BM (Figure 2.6c,d). However, these cells are absent in Nfil3–/–Zeb2egfp/+ mice.
In Nfil3+/+Zeb2egfp reporter mice, cDC1-specified CDPs can be identified as ZEB2-EGFPlo cells
that comprise 7% of CDPs (Figure 2.6c,d), which again are absent in Nfil3–/–Zeb2egfp/+ mice.
Finally, in Nfil3+/+Id2gfp reporter mice, cDC1-specified cells can be identified as CD117int Id2GFPhi cells that include pre-cDC1s and Id2-GFPhi CDPs and comprises approximately 2% of
Lin–CD135+ BM (Figure 2.6e,f). However, these cells are absent in Nfil3–/–Id2gfp mice. Further,
cDC1-specified CDPs can be identified as Id2-GFPhi cells that comprise 7% of the CDP (Figure
2.6e,f), but which are absent in Nfil3–/–Id2gfp mice. In summary, Nfil3 is required for the
development of all cDC1-specified progenitors identified by Zbtb46-GFP, ZEB2-EGFP, or Id2GFP.

Zeb2 functions downstream of Nfil3 in cDC1 specification
We next evaluated the interactions between Nfil3 and other factors using genetic mutants
rather than GFP reporters. We first examined interactions between Nfil3 and Zeb2. We crossed
Nfil3–/– mice to Zeb2f/fMx1-Cre mice in which ZEB2 can be inactivated by poly(I:C) treatment
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(Zeb2–/–). We compared cDC1 development and the presence of cDC1-specified progenitors in
Nfil3+/+Zeb2f/fMx1-cre- (wildtype), Nfil3–/–, Zeb2–/–, mice as well as Nfil3–/–Zeb2–/– mice (Figure
2.8). First, Zeb2–/– mice have more than a 2-fold increase in splenic cDC1s compared with
wildtype mice (Figure 2.8a,b), consistent with our previous study19. Further, Nfil3–/– mice lacked
cDC1s in spleen, as previously reported15. However, Nfil3 –/– Zeb2–/– DKO mice had a splenic
cDC1 population that, like Zeb2–/– mice, is about 2-fold greater than WT mice. Similarly, in
vitro cDC1 development was increased in Zeb2–/– BM and reduced in Nfil3–/– BM (Figure
2.8c,d). However, in vitro cDC1 development from Nfil3 –/– Zeb2–/– DKO BM was increased
compared to Nfil3–/– BM. Finally, we directly examined pre-cDC1 development in these mice.
Zeb2–/– mice have increased numbers of pre-cDC1 compared to wildtype mice, while Nfil3–/–
mice have greatly reduced numbers of pre-cDC1 (Figure 2.8e,f). However, Nfil3–/–Zeb2–/– DKO
mice have markedly restored pre-cDC1 development compared to Nfil3–/– mice. In summary, for
both in vivo and in vitro cDC1 development and for in vivo cDC1 specification, the phenotype of
Zeb2 deficiency dominates over that of Nfil3 deficiency, suggesting that Zeb2 genetically
functions downstream of Nfil3. The repression of Zeb2 by Nfil3 is required in the early stages of
cDC1 specification.

Zeb2 functions downstream of Id2 with respect to cDC1 specification
Some evidence suggests that Zeb2 may function genetically upstream of Id2 in cDC1
development18,19, but no mechanism has been established. To evaluate the genetic interaction
between Zeb2 and Id2, we crossed the Rosa26Cre-ERT2 strain with Zeb2f/f, Id2f/f, and Zeb2f/f Id2f/f
mice to produce mice in which tamoxifen administration can conditionally inactivate ZEB2
(Zeb2–/–), ID2 (Id2–/–), or both (Zeb2–/–Id2–/–) , respectively. We first evaluated pre-cDC1
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specification and cDC1 development in these mice (Figure 2.9a-d). Zeb2–/– mice show a 2-fold
increase in cDC1 and pre-cDC1 compared with wildtype mice, similar to mice with ZEB2
deficiency generated using poly(I:C) and Mx1-Cre (Figure 2.8). Id2–/– mice lack splenic cDC1,
as expected17, and also lack pre-cDC1 in BM. However, Zeb2–/–Id2–/– mice showed a restored
development of splenic cDC1 and BM pre-cDC1 (Figure 2.9a-d). Moreover, similar results were
obtained from in vitro Flt3L cultures of BM cells from these mice (Figure 2.10a,b). In summary,
for cDC1 development, Zeb2 deficiency dominates over Id2 deficiency in Zeb2–/–Id2–/– DKO
mice, suggesting that with respect to cDC1 specification, Zeb2 genetically functions downstream
of Id2.

Zeb2 functions upstream of Id2 with respect to Id2 expression
We next compared the transcriptional profiles of splenic cDC1 in wildtype, Zeb2–/–,
Zeb2–/– Id2–/–, and Nfil3 –/–Zeb2–/– mice using gene expression microarrays (Figure 2.9e,
Supplementary Figure 2.10c). cDC1 from all genotypes expressed high Irf8 and Batf3, and low
Irf4 and Tcf4, levels, as expected. Nfil3 was highly expressed in cDC1 isolated from wildtype,
Zeb2–/–, and Zeb2–/–Id2–/– mice and was absent in cDC1 isolated from Nfil3 –/– Zeb2–/– mice,
consistent with Nfil3 genetically functioning upstream of both Zeb2 and Id2. Further, Id2 was
expressed at the expected high levels in cDC1 from wildtype and Zeb2–/– mice, and absent in
cDC1 from Zeb2–/–Id2–/–mice, in agreement with Id2 genetically functioning upstream of Zeb2.
Unexpectedly, Id2 gene expression remained high in cDC1 from Nfil3 –/–Zeb2–/– mice, despite the
absence of Nfil3 normally required for cDC1 specification. These results indicate that, in the
absence of Nfil3, loss of Zeb2 is sufficient for Id2 induction, suggesting Zeb2 acts upstream of
Id2 with respect to Id2 expression.
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Id2 and Zeb2 expression are mutually repressive
The above results indicate that Zeb2 functions downstream of Id2 with respect to cDC1
specification, as ZEB2 deficiency can restore cDC1 in Id2–/– mice, but acts upstream of Id2 with
respect to Id2 gene expression. Thus, Id2 appears to repress Zeb2 expression, and Zeb2 appears
to repress Id2 expression, to create a circuit of mutual repression in which Nfil3 seems to initiate
cDC1 specification by repressing Zeb2.
This model predicts that cDC1 specification in the CDP could occur in the absence of
Id2, and that Id2–/– pre-cDC1 would maintain Zeb2 expression, unlike Id2+/+ pre-cDC1. To test
this, we used chimeric mice reconstituted with Id2–/–Zbtb46gfp/gfp BM (Id2–/–Zbtb46gfp/gfp). We
first confirmed that splenic pDCs and cDC2s develop normally in Id2–/–Zbtb46gfp/gfp chimeras
(Figure 2.11a). We also showed that Id2–/–Zbtb46gfp/gfp cDC2s are transcriptionally essentially
identical to Id2+/+Zbtb46gfp/+cDC2s (Figure 2.11b). Further, unspecified CDPs, defined as Lin–
CD117intZbtb46-GFP– CDPs, in Id2–/– mice are similar to Id2+/+and Batf3–/– CDPs, both in
frequency, expression of CD115 and CD135 (Figure 2.9f), and transcriptional profile (Figure
2.9g, Figure 2.11c). However, in Id2–/–Zbtb46gfp/gfp chimeras, cDC1-specified cells (Lin–
CD117intZbtb46-GFPpos) were present but were reduced in frequency by 3-fold. The cDC1specified cells in Id2–/–Zbtb46gfp/gfp chimeras maintained CD135 expression but had higher
expression of CD115 compared to Id2+/+Zbtb46gfp/+, implying a partial block in development of
specified cDC1s. In addition, these cells failed to induce Batf3 but maintained expression of
Zeb2 compared to Id2+/+ Zbtb46-GFPpos cells (Figure 2.9g and Figure 2.11c). These results
confirm a role for Id2 in inducing Batf3 and repressing Zeb2 expression during cDC1
specification. Since Id2 inhibits E protein transcription factors, Id2 might indirectly repress Zeb2
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if E proteins supported Zeb2 expression. In agreement, E2A is expressed in CDPs and binds to
E-box motifs in the Zeb2 locus based on ChIP-seq analysis (Figure 2.11d,e,f)35.

Id2 induction imposes a switch in Irf8 enhancer usage during cDC1 development
Data has revealed that E proteins may be necessary for the sufficient induction of Irf8 in
the CDP by activating the +41 kb Irf8 enhancer. This enhancer is transiently active during cDC1
progenitor development, but is required for the development of both pre-cDC1 and cDC1 in
vivo9,36. This 454 bp region contains six E-box motifs that are conserved between human and
murine Irf8 loci (Figure 2.12a) and is known to bind E2-2 in human pDCs (Figure 2.13)37. Using
the 454 bp region in a retroviral reporter system9, we found robust activity that was specific for
pDCs, but not cDC1s or cDC2 (Figure 2.12b,c). We also examined the activity of three
individual enhancer segments each containing 2 E-box motifs. Segments A and C showed
reduced overall activity compared with the 454 bp enhancer, but retained pDC specificity, while
the middle segment B retained overall activity, but reduced pDC specificity (Figure 2.12b,c).
Mutation of both E-boxes 1 and 2 in the 454 bp enhancer significantly reduced enhancer activity
in pDCs (Figure 2.14a,b). Within segment A, mutation of either E-box alone reduced overall
activity, while mutation of both E-boxes together completely extinguished activity (Figure 2.12d,
Figure 2.14c). The most active segment B was also E-box dependent, showing reduced overall
activity upon mutation of E-boxes 3 and 4 (Figure 2.13e, Figure 2.14d). These results indicate
that the +41 kb Irf8 enhancer activity relies on the redundant activity of the six E-box motifs
contained within this 454 bp region. In agreement with the role of Id2 in repressing E-box
motifs, overexpression of retroviral ID2 diminished +41 kb Irf8 enhancer activity (Figure 2.12f).
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This suggests that Id2 induction in the CDP can extinguish E protein activity at the +41
kb Irf8 enhancer, thereby imposing a requirement for a new enhancer in the pre-cDC1 to
maintain Irf8 expression necessary for cDC1 development. To identify a potential enhancer, we
performed ATAC-seq on MDP, CDP, and pre-cDC1 progenitors and found a peak that indicated
accessibility within the Irf8 region only in the pre-cDC1 and in mature cDC1, but not in the
earlier MDP or CDP or mature cDC2 (Figure 2.12g, red dashed line). This peak was located at
+32 kb of the Irf8 TSS and was shown to be BATF3-dependent9. The induction of Id2, and the
subsequent repression of Zeb2, thus forces a new requirement for Batf3 in maintaining Irf8
expression during cDC1 development.

2.4

Discussion
This study resolves several long-standing puzzles regarding cDC1 development. First,

Id2 was proposed to be required for cDC development by excluding pDC fate potential22,23, but
Id2–/– mice lacked only cDC1, and did not show the expected loss of all cDCs16. Second, cDC1
develop from CDP progenitors that express Irf8 independently of Batf3, yet later become
dependent on Batf3 to maintain Irf8 expression. The basis for this switch from Batf3independent to Batf3-dependent Irf8 expression was unclear. Third, mature cDC1 do not express
E proteins or show +41 kb Irf8 enhancer activity, yet their development requires both. These
apparent inconsistencies all result from a cryptic stage in cDC1 development in which Irf8
expression relies on the E protein-dependent +41 kb Irf8 enhancer. In this study, we examined
this cryptic stage of development to reveal the hierarchy of transcription factors governing cDC1
specification.
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Our results define a genetic hierarchy that unifies the actions of the known transcription
factors required for cDC1 development. cDC1s were known to require Irf8, Batf3, Id2, and Nfil3,
but how these factors interacted was unknown. We used Zbtb46-GFP to identify an earlier stage
of cDC1 specification than previously described that occurs within the CDP itself9. Single-cell
RNA-sequencing of the CDP identified a cluster of cells defined by the expression pattern of
Nfil3, Id2, and Zeb2. Epistatic analysis revealed a genetic hierarchy in which Nfil3 induces a
transition from CDPs that express high levels of Zeb2 and low levels of Id2, to CDPs that
express high levels of Id2 and low levels of Zeb2. A circuit of mutual repression between Zeb2
and Id2 stabilizes these distinct states, such that repression of Zeb2 by Nfil3 is required to induce
this transition. In Zeb2hi and Id2lo CDPs, Irf8 expression is maintained by the +41 kb Irf8
enhancer, which is dependent on E proteins for activity. Upon Id2 induction, E protein activity is
lost and Irf8 expression becomes dependent on Batf3 acting at the +32 kb Irf8 enhancer. It is
currently unclear whether Nfil3 directly represses Zeb2 and whether Zeb2 directly represses Id2,
as there may be other factors in this proposed genetic circuit. Nfil3 acts largely as a repressor
20,38

,but may activate transcription in contexts39. Likewise, Zeb2 has been suggested to directly

repress Id2 expression18,19, although this has not been rigorously tested. Nfil3, Zeb2, and Id2
have also been shown to regulate ILC development40, but the mechanisms by which these
transcription factors act in these cells has not been studied. It is possible that similar networks
like this exist in ILC development, and will require further study.
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Figure 2.1 Zbtb46-GFP Expression in CDPs Identifies the Earliest Committed cDC1
Progenitor.
a, BM from Zbtb46gfp/+ mice was analyzed by flow cytometry to identify pre-cDC1 as defined by
Zbtb46-GFP or by CD24 expression. Lineage (Lin) included CD3, CD19, NK1.1, Ly-6G, TER119, CD105, CD127 and Siglec-H. Numbers are the percent of cells in the indicated gates
(representative of three independent experiments, n = 3 mice). b, BM from Zbtb46gfp/+ mice was
analyzed by flow cytometry to identify the percentage of Zbtb46-GFP expression within the
30

CDP. Lineage was defined as in (a) (representative of three independent experiments, n = 3
mice). c, Zbtb46-GFPpos CDPs, Zbtb46-GFPneg CDPs, pre-cDC1 and pre-cDC2 were sort
purified from Zbtb46gfp/+ mice, cultured for 5 d in Flt3L, and analyzed by flow cytometry for
development of pDCs and cDC1 (representative of three independent experiments, n = 4 for
Zbtb46-GFPpos, Zbtb46-GFPneg CDPs, pre-cDC1 and n = 3 for pre-cDC2) d-e, Zbtb46-GFPpos
CDPs, Zbtb46-GFPneg CDPs, pre-cDC1 and pre-cDC2 were purified as in (c) and analyzed using
gene expression microarrays. Shown is expression of transcription factors with at least 4-fold
differences between Zbtb46-GFPneg CDP and pre-cDC1s (d) or hierarchical clustering for genes
with a least 8-fold differences between Zbtb46-GFPneg CDP and pre- cDC1s (e) (results averaged
from biological triplicates for Zbtb46-GFPpos CDPs, Zbtb46-GFPneg CDPs, and pre-cDC1 or
biological replicate for pre-cDC2).
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Figure 2.2 Single-cell RNA Transcriptome Analysis of CDPs.
a, CDPs gated as Live,[CD105, CD3, CD19, Ly6G, Ter119]–CD127–
CD117intCD115+CD135+MHC-II–CD11c– cells were purified by sorting from C57BL/6J mice.
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Shown are pre-sort (top) and post-sort (bottom) for cells collected for single-cell RNAsequencing. b, UMAP clustering of CDPs from Seurat analysis (data represents combined
analysis of two independent sequencing runs) c, Heatmap of 9,954 cells for the top ten genes of
each cluster from Seurat analysis. Shown are names of representative genes within each cluster.
d, Violin plots depicting cluster identity and expression level for the indicated genes expressed
in each cluster as described in (b). e, UMAP plots for the indicated genes as described in (b). f,
Joy plots depicting expression level and cell cycle stage for genes involved in the cell cycle.
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Figure 2.3 cDC1 specification occurs in the CDP
a, Zbtb46-GFPpos CDPs, Zbtb46-GFPneg CDPs, pre-cDC1 and pre-cDC2 were sort purified from
Zbtb46gfp/+ mice, cultured for 5 d in Flt3L, and analyzed by flow cytometry for development of
pDCs and cDC1 (data presented for three independent experiments, n = 4 for Zbtb46-GFPpos,
Zbtb46-GFPneg CDPs, pre-cDC1 and n = 3 for pre-cDC2). Small horizontal lines indicate the
mean. b, Violin plots depicting cluster identity and expression level for the indicated genes.
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Figure 2.4 Zeb2 and Id2 Heterogeneity Identifies cDC1 Specification in CDPs.
BM from Zeb2egfp/egfp (a) and Id2gfp (b) mice were analyzed by flow cytometry to identify GFP
expression in CDPs and pre-cDC1s. WT mice (Zeb2+/+ and Id2+/+) are shown as gray
histograms. Numbers indicate the percentage of cells in the indicated gates. (representative of
three independent experiments, n = 3 mice). c-d, ZEB2-EGFPlo and ZEB2-EGFPhi CDPs (c), and
Id2-GFPhi and Id2-GFPlo CDPs (d) were purified by sorting, cultured for 5 d in Flt3L, and
analyzed by flow cytometry for development of cDC1 (red) and cDC2 (blue) (representative of
three independent experiments, n = 5 for ZEB2-EGFPlo and ZEB2-EGFPhi CDPs and n = 4 for
Id2-GFPhi and Id2-GFPlo CDPs). e, The indicated cells purified as described in (c) and (d) or in
Figure 1c were cultured as in (c) and analyzed by flow cytometry for cDC1 development shown
as a percentage of total cDCs (CD45R–CD317–MHC-II+CD11c+) (pooled from three independent
experiments, n = 5 for ZEB2-EGFPlo and ZEB2-EGFPhi CDPs, n = 4 for Id2-GFPhi or Id2-GFPlo
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CDPs and Zbtb46-GFPpos or Zbtb46-GFPneg CDPs). Small horizontal lines indicate the mean. f,
Hierarchical clustering of genes expressed at least 5-fold differently between pre-cDC1 and
ZEB2-EGFPhi CDPs (results averaged from three independent experiments). g, Expression of the
indicated genes described in (f). h, Hierarchical clustering of genes expressed at least 5-fold
differently between pre-cDC1 and Id2-GFPlo CDPs (results averaged from two independent
experiments). i, Expression of the indicated genes described in (h). Data are presented as mean
and two-tailed unpaired Student’s t test was used to compare groups. *p < 0.05, **p < 0.01,
****p < 0.0001.
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Figure 2.5 ZEB2-EGFP and Id2-GFP Expression in BM and Spleen
a, BM from Zeb2egfp/egfp (left) and Id2gfp/+ (right) mice were analyzed by FACS to identify GFP
expression in the indicated progenitors. Numbers are the MFI (data representative of three
independent experiments, n = 3 mice). b, Spleen from Zeb2gfp/gfp (left) and Id2gfp/+ (right) mice
was analyzed by FACS for GFP expression in T cells (CD3+CD45R–), B cells (CD45R+CD3–),
NK cells (NK1.1+CD3–), monocytes (Ly6C+CD115+), and DCs as gated in the Methods. Numbers
are the MFI (data representative of three independent experiments, n =3 mice). c, Id2-GFPlo or
Id2-GFPhi CDPs were sort purified from Id2gfp/+ mice, cultured for 5 or 7 d in Flt3L, and analyzed
by FACS for development of cDC1 (red) or cDC2 (blue). Number indicates percentage of cells
in the gate (data representative of two independent experiments, n = 2 mice). d, Percentages of
cDC1s from in vitro cultures as described in (c). Small horizontal lines indicate the mean. e,
Zbtb46-GFPpos or Zbtb46-GFPneg CDPs were sort purified from Zbtb46gfp/+ mice, cultured for 5 or 7
d in Flt3L, and analyzed by FACS for development of pDCs (brown). Number indicate
percentage of cells in the gate (data representative of two independent experiments, n = 2 mice).
f, Percentages of pDCs from in vitro cultures as described in (e). Small horizontal lines indicate
the mean. g, ZEB2-EGFPlo or ZEB2-EGFPhi CDPs were sort purified from Zeb2egfp/egfp mice,
cultured for 5 or 7 d in Flt3L, and analyzed by FACS for development of pDCs (brown).
Number indicates percentage of cells in gate (data representative of two independent
experiments, n = 2 mice). h, Percentages of pDCs from in vitro cultures as described in (g).
Small horizontal lines indicate the mean. i, Id2-GFPlo or Id2-GFPhi CDPs were sort purified from
Id2gfp/+ mice, cultured for 5 or 7 d in Flt3L, and analyzed by FACS for development of pDCs
(brown). Number indicates percentage of cells in the gate (data representative of two
independent experiments, n = 2 mice). j, Percentages of pDCs from in vitro cultures as described
in (i). Small horizontal lines indicate the mean.
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Figure 2.6 Nfil3 is Required for cDC1 Specification in the CDP.
a, BM from Nfil3+/+Zbtb46gfp/+ and Nfil3–/–Zbtb46gfp/+ mice was analyzed by flow cytometry for
Lin–CD135+CD117int Zbtb46-GFPpos cells (left) or Zbtb46-GFPpos CDPs (right). Numbers
indicate the percent of cells in the indicated gates (representative of five independent
experiments, n = 5 mice). b, Cells from (a) are shown as a percentage of Lin–CD135+ (left) or
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CDPs (right). Small horizontal lines indicate the mean. c, BM from Nfil3+/+Zeb2egfp/+ and Nfil3–
/–
Zeb2egfp/+ mice was analyzed for Lin–CD135+CD117int ZEB2-EGFPlo cells (left) or ZEB2EGFPlo CDPs (right) (representative of three independent experiments, n = 6 mice). d, Cells
from (c) are shown as a percentage of Lin– CD135+ (left) or CDPs (right). Small horizontal lines
indicate the mean. e, BM from Nfil3+/+Id2gfp/+ and Nfil3–/–Id2gfp/+ mice was analyzed for Lin–
CD135+CD117intId2-GFPhi cells (left) or Id2-GFPhi CDPs (right) (representative of three
independent experiments, n = 3 for Nfil3+/+Id2gfp/+ mice and n = 4 for Nfil3–/–Id2gfp/+ mice). f,
Cells from (e) are shown as a percentage of Lin– CD135+ (left) or CDPs (right). Small horizontal
lines indicate the mean .Data in b, d, and f are presented as mean and two-tailed unpaired
Student’s t test was used to compare groups. ***p < 0.001; ****p < 0.0001.
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Figure 2.7 Nfil3 is Required for cDC1 Specification
a, BM from Zbtb46gfp/+ (WT), Nfil3–/–Zbtb46gfp/+ and Batf3–/–Zbtb46gfp/+ mice was analyzed by FACS
for development of pre-cDC1 (left), Lin–CD135+CD117intZbtb46-GFPpos (middle) and Zbtb46GFPpos CDPs (right) (data representative of three independent experiments, n = 3 mice).
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Figure 2.8 Zeb2 is Downstream of Nfil3 in cDC1 Development.
a, Splenic cDCs from Nfil3+/+Zeb2f/f Mx1-cre– (WT), Zeb2f/f Mx1-cre+ (Zeb2–/–), Nfil3–/– (Nfil3–/–
), and Nfil3–/– Zeb2f/f Mx1-cre+ (Nfil3–/– Zeb2–/–) mice were analyzed for cDC1 (red) and cDC2
(blue) frequency. Numbers are the percent of cells in the indicated gates (data representative of
three independent experiments, n = 7 for WT and Zeb2–/– mice, n = 8 for Nfil3–/– mice and n = 9
for Nfil3–/– Zeb2–/– mice). b, Analysis from (a) are presented as individual mice. Small horizontal
lines indicate the mean. c, cDCs derived in vitro from Flt3L-treated BM cultures from mice in
(a) were analyzed for cDC1 (red) and cDC2 (blue) frequency as in (a) (data representative of
three independent experiments, n = 7 for WT and Zeb2–/– mice, n = 8 for Nfil3–/– mice, and n = 9
for Nfil3–/– Zeb2–/– mice). d, Analysis from (c) are presented for individual mice. Small
horizontal lines indicate the mean. e, BM from mice in (a) was analyzed for the frequency of
pre-cDC1 (red). BM cells are pre-gated as Lin– SiglecH–CD135+ (data representative of three
independent experiments, n = 7 for WT and Zeb2–/– mice, n = 8 for Nfil3–/–mice, and n = 9 for
Nfil3–/– Zeb2–/– mice). f, Analysis from (e) are presented for individual mice. Small horizontal
lines indicate the mean. Mean and two-tailed unpaired Student’s t test was used to compare
groups. *p < 0.05; ****p < 0.0001; ns, not significant.
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Figure 2.9 Expression of Id2 and Zeb2 is Mutually Repressive in the CDP.
a, Splenic cDCs harvested from WT, Zeb2f/f Rosa26 (cre-ERT2/+) (Zeb2–/–), Id2f/f Rosa26 (cre-ERT2/+)
(Id2–/–), and Id2f/f Zeb2f/f Rosa26 (cre-ERT2/cre-ERT2) (Zeb2–/– Id2–/– ) were analyzed for cDC1 (red)
and cDC2 (blue) frequency. Numbers are the percent of cells in the indicated gates (data
representative of two independent experiments, n = 2 for Id2–/– mice, n = 3 for Zeb2–/– Id2–/–
mice, n = 4 for Zeb2–/– mice, and n = 5 for WT mice). b, Data from (a) are presented for
individual mice. Small horizontal lines indicate the mean. c, BM from mice in (a) was analyzed
for the frequency of pre-cDC1 (red). BM cells are pre-gated as Lin– SiglecH–CD135+ (data
representative of two independent experiments, n = 2 for Id2–/– mice, n = 3 for Zeb2–/– Id2–/–
mice, n = 4 for Zeb2–/– mice, and n = 5 for WT mice). d, Data from (c) are presented for
individual mice. Small horizontal lines indicate the mean. e, Shown is the expression of Irf8,
Nfil3, and Id2 in splenic cDC1 sorted from WT, Zeb2–/–, Zeb2–/– Id2–/– , and Zeb2–/– Nfil3–/– mice
(n = 3 for WT and Zeb2–/– mice, n = 2 for Zeb2–/– Id2–/– and Zeb2–/– Nfil3–/– mice). Small
horizontal lines indicate the mean. f, BM from Zbtb46gfp/+(WT), Id2–/–Zbtb46gfp/gfp (Id2–/–), and
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Batf3–/–Zbtb46gfp/gfp (Batf3–/–) mice was gated as Lin– cells, and the CD117intZbtb46-GFP–- (red)
or CD117intZbtb46-GFP+ (blue) cells were separately analyzed for CD115 and CD135
expression (data representative of five independent experiments, n = 5 mice) g, CDPs and
Zbtb46-GFPpos cells in (f) were sort purified and analyzed by gene expression microarray.
Shown are gene expression levels for Zeb2, Nfil3, and Batf3 (data representative of three
independent experiments, n = 2 for CDPs and n = 3 for Zbtb46-GFPpos cells). Small horizontal
lines indicate the mean. Data are shown as mean and two-tailed unpaired Student’s t test was
used to compare groups. *p < 0.05, ***p < 0.001, ns, not significant.
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Figure 2.10 Id2-Zeb2 Loop Regulates cDC1 Fate
a, cDCs derived in vitro from Flt3L-treated BM cultures from WT, Zeb2–/–, Id2–/– , and Zeb2–/– Id2–
/–
mice were analyzed for cDC1 (red) and cDC2 (blue) frequency. Numbers are the percent of
cells in the indicated gates (data representative of two independent experiments, n = 2 for Id2–/–
mice, n = 3 for Zeb2–/– Id2–/– mice, n = 4 for Zeb2–/– mice, and n = 5 for WT mice). b, cDC1
frequency is shown for individual mice in (a) as a percentage of total cDCs. Small horizontal
lines indicate the mean. c, Splenic cDC1 from WT, Zeb2–/–, Id2–/–, and Zeb2–/– Id2–/– mice were
purified by sorting and analyzed by gene expression microarrays. Shown are expression for the
indicated genes for each genotype. Numbers are the average gene expression of three biological
replicates.
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Figure 2.11 Id2 Does Not Regulate cDC2 Development or Transcriptome, But May
Indirectly Repress Zeb2 through E proteins
a, Spleens from radiation chimeras receiving either Zbtb46gfp+ (WT) or Id2–/–Zbtb46gfp/gfp (Id2–/–) BM
were analyzed by FACS for the frequency of pDC (left), and cDC1 and cDC2 (middle)
populations, and for Zbtb46-GFP expression on cells gated on cDC2 populations (right) (data
representative of three independent experiments, n = 3 mice) b, Microarray analysis of Id2+/+ and
Id2–/– cDC2. Gene expression comparing Id2+/+ cDC2 to Id2–/–cDC2 described in (a) are shown
(left), or WT cDC2 compared to WT cDC1 (right) (data pooled from two independent
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experiments, n = 2 mice). 255 genes were at least 2-fold differentially expressed between Id2+/+
and Id2–/– cDC2. Green lines indicate two-fold change threshold c, Gene expression microarray
was performed on two CDP populations, sort purified separately as either Lin- CD117intZbtb46GFPneg (GFP-), or Lin- CD117intZbtb46-GFPpos (GFP+) cells, from each of three genotypes,
Zbtb46gfp/+ (WT), Id2-/-Zbtb46gfp/gfp (Id2–/–), and Batf3-/-Zbtb46gfp/gfp (Batf3–/–) mice. Shown are averages
of duplicate or triplicate gene expression values of the indicated genes in the indicated
populations. d, BM from E2A-GFP reporter mice (Tcf3gfp/+) or WT (gray histograms) were
analyzed for GFP expression in CDPs (left), or as an overlay (right) for pre-cDC1 (red) and
CDP (blue) (data representative of four independent experiments, n = 5 mice). e, Shown are E2A and CTCF peaks identified by ChIP-seq in HPC-7 cells at the Zeb2 locus (mm9)35. Squares
represent E-box motifs (CANNTG) within the indicated enhancer regions. f, Proposed epistatic
model for Nfil3, Id2, Zeb2, E protein, and cDC1 fate.
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Figure 2.12 Id2 imposes a switch from the +41 kb Irf8 enhancer to the +32 kb Irf8 enhancer
by Reducing E protein activity,
a, Conservation of E-box motifs between human (red) and mouse (blue) loci within the +41 kb
Irf8 enhancer. b, GFP expression from RV reporters with (IRF8 +41) or without (empty) the 454
bp +41 kb enhancer, or with intact segment A (A), intact segment B (B), intact segment C (C), or
intact segments A and B (A+B), or intact segments B and C (B+C), in pDCs, cDC1s, and cDC2s,
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shown as histograms (data pooled from >5 independent experiments, n > 5). c, Data shown in
(b) shown as integrated MFI (data pooled from >5 independent experiments, n > 5). Small
horizontal lines indicate the mean. d, GFP expression in pDCs of RV reporters without (empty)
or with the 454 bp +41 kb enhancer (IRF8 +41), or with intact segment A (A), or with mutations
in E-box 1 (A-m1), E-box 2 (A-m2) or both (A-m1/m2), shown as integrated MFI (data pooled
from >5 independent experiments, n > 5). Small horizontal lines indicate the mean. e, GFP
expression in pDCs of RV reporters without (empty) or with the 454 bp +41 kb enhancer (IRF8
+41), or with intact segment B (B), or with mutations in E-box 3 (B-m3), E-box 4 (B-m4) or
both (B-m3/m4), shown as integrated MFI (data pooled from >5 independent experiments , n >
5). Small horizontal lines indicate the mean. f, GFP expression in WEHI-231 cells of RV
reporters with (IRF8 +41) or without (empty) the 454 bp +41 kb enhancer, or with intact segment
A (A), intact segment B (B), intact segment C (C) and co-transduced with either empty RV
(gray) or ID2 RV (purple), shown as integrated MFI (data pooled from three independent
experiments, n = 3). Small horizontal lines indicate the mean. g, ATAC-Seq was performed on
the indicated progenitor or DC populations. Shown is the Irf8 locus, with the Irf8 +41 kb
enhancer region (black box) and the +32 kb enhancer region (dotted box). (representative of
three independent experiments and the Immunological Genome Project Open Chromatin
Regions, n= 1 biological replicate per population). Data are presented as mean and one-way or
two-way ANOVA was used to compare groups. *p < 0.05, **p < 0.01, ****p < 0.0001.
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Figure 2.13 Conservation of +41 kb Enhancer Between Human and Mice
a, ChIP-seq peaks for E2-2 (E2-2) or control (input) for human IRF8 locus37. Numbers are
chromosomal coordinates, human chromosome 16, draft genome hg19. Box indicates E2-2
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binding peak corresponding to mouse +41 kb Irf8 enhancer. b, Consensus human E-box motif
from E2-2 track. c, FIMO analysis depicting p-values of predicted E-boxes in human IRF8
chr16:85991064-85991633 (+58 kb from IRF8 TSS) d, Alignment of human, genome draft
hg19, and mouse, genome draft mm10, for the +41 kb IRF8 enhancer regions. Conserved human
(red box) and mouse (blue underlined) E-box motifs are indicated.
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Figure 2.14 Activity of +41 kb Irf8 Enhancer is E-box Dependent
a, GFP expression in pDCs, from RV reporters without (empty) or with the entire 454 bp +41 kb
enhancer region (IRF8 +41), or with single or double mutations of the indicated E-boxes (left)
(data representative of at least three independent experiments, n > 3). b, Data shown in (a)
shown as integrated MFI (data pooled from at least three independent experiments, n > 3). Small
horizontal lines indicate the mean. c, GFP expression in pDCs of RV reporters without (empty)
or with the 454 bp +41 kb enhancer (IRF8 +41), or with intact segment A (A), or with mutations
in E-box 1 (A-m1), E-box 2 (A-m2) or both (A-m1/m1), shown as histograms (data
representative of at least three independent experiments, n > 3). d, GFP expression in pDCs of
RV reporters without (empty) or with the 454 bp +41 kb enhancer (IRF8 +41), or with intact
segment B (B), or with mutations in E-box 3 (B-m3), E-box 4 (B-m4) or both (B-m3/m4), shown
as histograms (data representative of at least three independent experiments, n > 3). Data are

52

presented as mean and one-way ANOVA was used to compare groups. *p < 0.05, **p < 0.01,
****p < 0.0001.

53

2.5

Materials and Methods

Mice
WT C57BL6/J mice were obtained from The Jackson laboratory. Zbtb46gfp/+ mice were
described25. Nfil3−/− mice were from A. Look and Tak Mak46. Mx1-Cre [B6.Cg-Tg(Mx1cre)1Cgn/J] mice (stock no. 003556), and Rosa26Cre/Cre [B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J]
mice (stock no. 008463) were obtained from The Jackson Laboratory. B6.SJL (B6.SJL-Ptprca
Pepcb /BoyJ) mice (strain code 564), were obtained from Charles River. ZEB2-EGFP fusion
protein reporter (STOCK Zfhxlbtm2.1Yhi) mice33 were derived from biological material provided by
the RIKEN BioResource Center through the National BioResource Project of the Ministry of
Education, Culture, Sports, Science and Technology, Japan. SIP1flox(ex7) (Zeb2f/f) were from Y.
Higashi47. For experiments shown in Figure 2.9f,g, Id2-CreERT2 mice (JAX stock #016222)48
were bred to Zbtb46gfp mice to generate Id2creERT2/+Zbtb46gfp/+ mice. These mice were crossed to
generate Id2creERT2/creERT2 Zbtb46gfp/+ or gfp/gfp mice. Livers from day 1 old Id2creERT2/creERT2 pups
were dispersed and cells injected into 4-6 week old lethally irradiated SJL WT mice (Charles
Rivers) and chimeras used eight weeks after reconstitution. Id2-flox and Id2-IRES-GFP mice34
were generously donated by G. Belz. Tcf3GFP/+ were generated by crossing the Tcfe2afl allele
(B6.129-Tcf3tm1Mbu/J JAX stock #028184) with Vav-iCre mice (JAX stock #008610).
All mice were generated, bred, and maintained on the C57BL/6 background in the Washington
University in St. Louis School of Medicine specific pathogen-free animal facility. Animals were
housed in individually ventilated cages covered with autoclaved bedding and provided with
nesting material for environmental enrichment. Up to five mice were housed per cage. Cages
were changed once a week, and irradiated food and water in autoclaved bottles were provided ad
libitum. Animal manipulation was performed using standard protective procedures, including
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filtered air exchange systems, chlorine-based disinfection, and personnel protective equipment
including gloves, gowns, shoe covers, face masks, and head caps. All animal studies followed
institutional guidelines with protocols approved by the Animal Studies Committee at
Washington University in St. Louis.
Unless otherwise specified, experiments were performed with mice between 6 and 10
weeks of age. No differences were observed between male and female mice in any assays
performed and so mice of both genders were used interchangeably throughout this study. Within
individual experiments, mice used were age- and sex-matched littermates whenever possible.

Antibodies and flow cytometry
Cells were kept at 4ºC while being stained in PBS supplemented with 0.5% BSA and
2mM EDTA in the presence of antibody blocking CD16/32 (clone 2.4G2; BD 553142). All
antibodies were used at a 1:200 dilution vol/vol (v/v), unless otherwise indicated.
The following antibodies were from BD: Brilliant Ultraviolet 395–anti-CD117 (clone 2B8,
catalog number 564011, 1:100 v/v), PE-CF594–anti-CD135 (clone A2F10.1, catalog number
562537, 1:100 v/v), V500–anti-MHC-II (clone M5/114.15.2, catalog number 742893), Brilliant
Violet 421–anti-CCR9 (clone CW-1.2, catalog number 565412, 1:100 v/v), Alexa Fluor 700–
anti-Ly6C (clone AL-21, catalog number 561237), Brilliant Violet 421–anti-CD127 (clone
SB/199, catalog number 562959, 1:100 v/v), biotin–anti-CD19 (clone 1D3, catalog number
553784), BV510–anti-CD45R (clone RA3-6B2, catalog number 563103), PE-anti-CD90.1 (clone
OX-7, catalog number 554898). The following antibodies were from eBioscience:
allophycocyanin–anti-CD317 (clone eBio927, catalog number 17-3172-82, 1:100 v/v), PE-Cy7–
anti-CD24 (clone M1/69, catalog number 25-0242-82), peridinin chlorophyll protein (PerCP)–
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eFluor 710–anti-CD172a (clone P84, catalog number 46-1721-82), PerCP-Cy5.5–anti-SiglecH
(clone eBio-440c, catalog number 46-0333-82), PE–anti-CD11c (clone N418, catalog number
12-0114-82).
The following antibodies were from BioLegend: Brilliant Violet 711–anti-CD115 (clone
AFS98, catalog number 135515, 1:100 v/v), PE or Brilliant Violet 421–anti-XCR1 (clone ZET,
catalog number 148204 or 148216), Alexa Flour 700 or APC/Cy7-–anti-F4/80 (clone BM8,
catalog number 123130 or 123118, 1:100 v/v), PE–anti-CD45.2 (clone 104, catalog number
109808), biotin or PE/Dazzle 594–anti-CD45R (clone RA3-6B2, catalog number 103203 or
103258), biotin–anti-Ly6G (clone 1A8, catalog number 127603), biotin–anti-Ter119 (clone
TER-119, catalog number 116204), biotin–anti-CD105 (clone MJ/718, catalog number 120404),
biotin–anti-NK1.1 (clone PK136, catalog number 108704), biotin–anti-CD127 (clone A7R34,
catalog number 135006, 1:100 v/v), biotin–anti-Ly-6A/E (clone D7, catalog number 108104),
PE-anti-human-CD4 (clone RPA-T4, catalog number 300550, 1:50 v/v). The following
antibodies were from Tonbo Bioscience: FITC–anti-CD45.1 (clone A20, catalog number 350453-U500), biotin or APC–anti-CD3e (clone 145-2c11, catalog number 30-0031-U500 or 200032-U100), violetFluor 450–anti-MHC Class II (I-A/I-E) (clone M5/114.15.2, catalog number
75-5321-U100). The following antibodies were from Invitrogen: allophycocyanin–eFluor 780–
anti-CD11c (clone N418, catalog number 47-0114-82). Cells were analyzed on a FACSCanto II
or FACSAria Fusion flow cytometer (BD), and data were analyzed with FlowJo v10 software
(TreeStar).

Induced Gene Deletion
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Conditional gene deletion in Nfil3–/–Zeb2f/fMx1-cre (Nfil3–/– Zeb2–/–), Zeb2f/f Mx1-creNfil3+/+ (WT), Zeb2f/f Mx1-cre- Nfil3–/– (Nfil3–/–) and Zeb2f/f Mx1-cre+ Nfil3+/+ (Zeb2–/–) mice was
induced by i.p. injection of 150 μg poly(I:C) (SigmaAldrich; 1.0 mg/mL stock solution dissolved
in saline) twice within 36–72 h. Gene deletion in WT, Zeb2f/f Rosa26Cre-ERT2 (Zeb2–/–), Id2f/f
Rosa26Cre-ERT2 (Id2–/–) and Zeb2f/f Id2f/f Rosa26Cre-ERT2 (Zeb2–/– Id2–/–) mice was induced by
administration of tamoxifen citrate chow (Envigo) for 4–5 weeks. Mice were given up to 2 d of
regular chow per week if significant weight loss was observed. After treatment, mice were
rested on regular chow for one week before analysis.

Isolation and culture of BM progenitor cells and splenic DCs
Bone marrow progenitors and DCs were isolated as described9. For BM sorting
experiments, BM was isolated and depleted of CD3-, CD19-, CD105-, Ter119-, and in some
instances Ly6G- and CD45R-expressing cells by staining with the corresponding biotinylated
antibodies followed by depletion with MagniSort Streptavidin Negative Selection Beads
(Thermo Fisher). All remaining BM cells were then stained with fluorescent antibodies prior to
sorting. MDPs were identified as Lin–CD117hiCD135+CD115+ BM cells; CDPs were Lin–
CD117intCD135+CD115+MHC-II–CD11c+; pre-cDC1s are Lin–CD117intCD135+CD115–MHCIIlo-intCD11c+CD24+Siglec-H– or as Lin–CD117intCD135+MHC-IIlo-intCD11c+Siglec-H–Zbtb46GFP+, and pre-cDC2s as Lin–CD117loCD135+CD115+MHC-II–CD11c+. For splenic sorting
experiments, spleen was isolated and depleted of Ly6G-, B220-, and CD3-expressing cells.
cDC2 were identified as Lin–CD45R–CD317–MHC-II+CD11c+CD172a+ cells. Cells were
purified on a FACSAria Fusion into IMDM plus 10% FBS with 5% Flt3L conditioned media.
Sort purity of >95% was confirmed by post-sort analysis before cells were used for further
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experiments. For experiments that included Flt3L cultures, sorted cells (1×103 to 10×103 cells
per 200 µl complete IMDM) were cultured for 5 or 7 d at 37 °C with 5% Flt3L conditioned
media.

Expression microarray analysis
RNA was extracted with a RNAqueous-Micro Kit (Ambion) or a NucleoSpin RNA XS
Kit (Machery-Nagel), then was amplified with Ovation Pico WTA System (NuGEN) or WT Pico
System (Affymetrix) and hybridized to GeneChip Mouse Gene 1.0 ST microarrays (Affymetrix)
for 18 h at 45 °C in a GeneChip Hybridization Oven 640. The data was analyzed with the
Affymetrix GeneChip Command Console. Microarray expression data was processed using
Command Console (Affymetrix, Inc) and the raw (.CEL) files generated were analyzed using
Expression Console software with Affymetrix default RMA Gene analysis settings (Affymetrix,
Inc). Probe summarization (Robust Multichip Analysis, RMA), quality control analysis, and
probe annotation were performed according to recommended guidelines (Expression Console
Software, Affymetrix, Inc.). Data were normalized by robust multiarray average summarization
and underwent quartile normalization with ArrayStar software (DNASTAR). Unsupervised
hierarchical clustering of differentially expressed genes was computed with ArrayStar
(DNASTAR) with the Euclidean distance metric and centroid linkage method.

Single-cell RNA-sequencing
100,000 CDPs were sort purified as Live,[CD105, CD3, CD19, Ly6G, Ter119]–CD127–
CD117intCD115+CD135+MHC-II–CD11c– cells and single-cell gene measured with the
Chromium system using Chromium Single Cell 3’ Library and Gel Bead Kit v2 (10X
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Genomics). Cell density and viability of sorted cells were determined by Vi-CELL XR cell
counter (Beckman Coulter), and all processed samples had cell viability at >90%. The cell
density was used to impute volume of single cell suspension needed in the reverse transcription
(RT) master mix, to achieve ~6,000 cells per sample. After Gel Bead-in-Emulsion reverse
transcription (GEM-RT) reaction and clean-up, a total of 12 cycles of PCR amplification was
performed to obtain cDNAs. Libraries for RNA-seq were prepared following the manufacturer’s
user guide (10x Genomics), profiled using Bioanalyzer High Sensitivity DNA kit (Agilent
Technologies) and quantified with Kapa Library Quantification Kit (Kapa Biosystems). Each
single-cell RNA-seq library was sequenced in one lane of HiSeq4000 (Illumina).
Sequencing data were pooled from two runs of 4,796 and 4,758 individual cells. Run 1 had
2,354 median genes and 85,247 means reads per cell. Run 2 had 2,247 median genes and 85,265
mean reads per cell. Sequencing was filtered and processed using the Seurat R toolkit49.

ATAC-Seq
ATAC-Seq of DC progenitors was performed using the Omni-ATAC protocol as
previously described with minor modifications36. 10,000 MDPs, CDPs, and pre-cDC1s were
sorted from bone marrow as described above and lysed in ice-cold ATAC-RSB buffer containing
0.1% NP40, 0.1% Tween-20, and 0.01% digitonin. Cells were incubated at 4° C for 3 min, then
washed with ATAC-RSB buffer containing only 0.1% Tween-20. Nuclei were spun down by
centrifugation and then incubated in 50 µL of transposition buffer (25 µL 2X TD buffer, 22.5 µL
dH2O, 2.5 µL Tn5 transposase (Nextera DNA Library Prep Kit, Illumina)) and incubated at 37°
C for 30 min. If 10,000 cells could not be obtained for a certain population then the quantity of
Tn5 transposase was titrated down proportionately to the number of cells obtained but cells were
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still incubated in 50 µL total. Transposed DNA was purified with a DNA Clean & Concentrator
kit (Zymo Research), eluted in 21 µL of elution buffer, and stored at -20° C until amplification.
Three biological replicates for each cell population were obtained and sequenced. ATAC-Seq
libraries were prepared as previously described, barcoded and sequenced on an Illumina Nextseq.

Retroviral analysis of murine +41 kb Irf8 enhancer
The 454 bp region of the +41 kb Irf8 enhancer was cloned into hCD4 pA GFP-RV9.
Each E-box motif (CANNTG) in the enhancer was mutated to a binding site-free DNA sequence
(AACTAC) determined by SiteOut50.
The primer sequences for the entire enhancer and the associated mutations are as follows:
for +41 kb Irf8 enhancer: aaaagatctGATCTGGGGTATGTGGGAAC
and GAAAGAAGATCTGGGGTATGT; for segment A:
aaaagatctGATCTGGGGTATGTGGGAAC and
aaaaaagcttTGTGCTAATTAAAGCCAAGAGG; for segment B:
aaaaggatccCTGTACCCCAGATCCCATC and aaaaaagcttGAGGAACCACCACTCAAGG; for
segment C: aaaaggatccTCAGGTTTGGGGAAGAAG and
aatcttttattttatcgatagcaagCTTGACACTCTGGGAATAG; for segment A+B:
GCGACGGTCGCGCGAGCtagaaaagatctGATCTGGGGTATGTGGG and
aatcttttattttatcgataaaaaaagcttGAGGAACCACCACT; for segment B+C:
aaaaggatccCTGTACCCCAGATCCCATC and
aatcttttattttatcgatagcaagCTTGACACTCTGGGAATAG; for mE1:
GTGTCTCTCACaactacGGATCCCATATAAGGTTTATTTTTAC
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and CCTTATATGGGATCCgtagttGTGAGAGACACAAAGGGTTC; for mE2:
GCCCAGGCCCaactacTTCCCCCCTGTACCCCAG and
GTACAGGGGGGAAgtagttGGGCCTGGGCGATGTTCTG; for mE3:
TCCTCCTCTGGTAGAGAAGAAGCTGCGGGCTGGGaactacCCGCACCCTCCCC
and GGGGAGGGTGCGGgtagttCCCAGCCCGCAGCTTCTTCTCTACCAGAGGAGG; for
mE4: GCACCCTCCCCGGaactacTCTTCACCGTGCGGTCAGG
and CGCACGGTGAAGAgtagttCCGGGGAGGGTGCGGg; for mE5:
GGCTGGAAGCCTTGAGTGGTGGTTCCTCaactacTCTTTGGGCACCTG
and CAGGTGCCCAAAGAgtagttGAGGAACCACCACTCAAGGCTTCCAGCC; for mE6:
ctacTCTTTGGGaactacGGATGCGTCCTGTTAGGACC and
CCTAACAGGACGCATCCgtagttCCCAAAGAgtagttGAGG; and for mE3/4:
AGCTGCGGGCTGGGaactacCCGCACCCTCCCCGGaactacTCTTCACCGT
and ACGGTGAAGAgtagttCCGGGGAGGGTGCGGgtagttCCCAGCCCGCAGCT.
Retroviral vectors were transfected into Plat-E cells with TransIT-LTI (Mirus Bio) and viral
supernatants were collected two days later. For retroviral analysis in Flt3L cultures, Lin–
CD117high BM cells were infected on day 1 after plating with the supernatants of transfected
packaging cells and concentrated by centrifugation with 2 ug/ml polybrene by ‘spin infection’ at
2,250 r.p.m. for 60 min. Viral supernatant was replaced by complete IMDM + 5% Flt3L one day
after transduction and the culture was read out on day 8. For analysis, the enhancer activity was
quantitated using integrated MFI51,52.
For retroviral analysis in WEHI-231 cultures, WEHI-231 cells were infected on day 1
after plating with supernatants of transfected packaging cells with the reporter constructs and
either empty or ID2 retrovirus and concentrated by centrifugation with 2 ug/ml polybrene by
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‘spin infection’ at 2,250 r.p.m. for 60 min. Viral supernatant was replaced by complete IMDM
one day after transduction and the culture was read out on day 3.For analysis, the enhancer
activity was quantitated using integrated MFI in cells that were co-infected with either empty or
ID2 retrovirus51,52.

Analysis of E-box motifs in human +58 kb IRF8 enhancer
The occurrence of E-box motifs in the element +41 kb relative to the Irf8 TSS was
found with FIMO53 motif-identification program at a P-value threshold of 1 × 10 −3 with the Ebox position weight matrix obtained for the E2-2 peaks of human pDCs37. Human and mouse
elements were aligned via Clustal Omega W.

QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis for single cell RNA-sequencing data is described above. Horizontal
lines in figures indicate the mean. Results from independent experiments were pooled as
indicated in figure legends. Data were analyzed using Prism (GraphPad), using unpaired twotailed Student's t tests when comparing two groups or ordinary one-way or two-way
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CHAPTER 3:
Regulations of Zeb2 expression in adult and embryonic hematopoiesis

The contents of this chapter are under review in Immunity. Huang X*, et al. Differential usage
of Zeb2 enhancers distinguishes adult and embryonic hematopoiesis. Manuscript under review in
Immunity.
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3.1

Abstract
The transcriptional repressor Zeb2 regulates development of many cell fates among

somatic, neural, and hematopoietic lineages, but the basis for its requirement in these diverse
linages is unclear. Our recent study uncovered a mutually repressive regulatory circuit between
Id2 and Zeb2 and predicted that Zeb2 should be positively regulated by members of the E protein
family of transcription factors. Here, we identified a 400bp enhancer region located 165
kilobases (kb) upstream of the Zeb2 transcriptional start site (TSS) that binds the E proteins, E2A
and E2-2, at several E-box motifs and is active in hematopoietic lineages. Germline deletion of
this 400bp region (Zeb2 –165–/– mice) specifically prevented Zeb2 expression in hematopoietic
stem cell (HSC) derived lineages. Zeb2 –165–/– mice lacked development of pDCs, monocytes,
and B cells. Surprisingly, all macrophages in Zeb2 –165–/– mice were exclusively of embryonic
origin. Using single-cell chromatin profiling, we identified a second Zeb2 enhancer located at
+164kb that is selectively active in embryonically derived lineages, but not in lineages derived
from HSCs. Thus, Zeb2 expression in adult, but not embryonic, hematopoiesis is selectively
controlled by the –165kb Zeb2 enhancer.

3.2

Introduction
Hematopoiesis requires precise control by lineage-determining transcription factors (TFs)

whose expression is regulated mainly by cis-acting enhancer elements 1-4. Multiple enhancers
may act within a single locus to control gene expression in different cell types 5,6. Enhancer
usage can change dynamically during the differentiation of progenitor cells, reflecting distinct
gene expression profiles enforced by transcriptional circuitries at different stages of lineage
development 7,8.
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Dendritic cells (DCs) and tissue-resident macrophages (RTMs) are two closely-related
mononuclear phagocytic lineages that are important in antigen presentation and induction of
adaptive immunity 9-11. DCs are comprised of classical dendritic cells (cDCs) and plasmacytoid
DCs (pDCs) 9,12, and are derived from HSCs during definitive hematopoiesis 13,14. By contrast,
RTMs can develop both from transient definitive hematopoiesis during embryogenesis and from
definitive hematopoiesis in the adult 15. During transient definitive hematopoiesis, EMPs can
differentiate locally into YS MFs or migrate to the FL to produce monocytes 15. YS MFs and FL
monocytes are the precursors that give rise to the majority of RTMs in the adult 16,17. During
adult definitive hematopoiesis, BM-derived circulating monocytes can also contribute to the
RTM population, but it is not known whether embryonic RTM development relies on the same
transcriptional mechanisms as in the adult 15,18.
Zinc finger E-box binding homeobox 2 (Zeb2) is a transcriptional repressor required for
both DC and MF lineages 19-21. ZEB2 was identified as a SMAD-interacting protein regulating
epithelial-mesenchymal transition 22-25. Zeb2 acts in development of the nervous system and
melanocytes 28,29 and germline deletion of Zeb2 in mice causes embryonic lethality 26,27.
Conditional deletion of Zeb2 in hematopoietic lineages causes a defect in HSC mobilization and
results in neonatal lethality 30. Zeb2 functions in NK cell maturation 31, in terminally
differentiated T cells 32-35, and inducible deletion of Zeb2 in adult mice with an Mx1-cre system
resulted in a 5-fold reduction in B cell numbers in peripheral blood 36. Zeb2 is also required for
development of dendritic cells 37 , monocytes 19, and for the maintenance of RTM identity 21,
suggesting that Zeb2 is active in cells derived both from embryonic and adult hematopoiesis.
Despite its essential role in the development of multiple hematopoietic lineages 38,39, the
transcriptional regulation of Zeb2 is incompletely characterized. Some studies have suggested
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that the TF T-bet might regulate Zeb2 expression in T cells and NK cells 31,32,34, while another
study implicated c-Myb as important for Zeb2 expression in CD8 T cells 40. We recently
described a transcriptional circuit of mutual repression between Id2 and Zeb2 operating in the
common dendritic cell progenitor (CDP) to resolve the fate choice between pDCs and type 1
cDCs (cDC1) 37,41. Since Id2 can act by inhibiting the activity of E-proteins, we proposed that E
proteins may positively regulate Zeb2 expression in the CDP but did not identify the regulatory
elements that might mediate this control.
Here, we used chromatin immunoprecipitation and sequencing (ChIP-seq) and assay for
transposase-accessible chromatin using sequencing (ATAC-seq) to identify potential regulatory
regions in the Zeb2 locus. We found an enhancer located 165kb upstream of the Zeb2
transcriptional start site (TSS) that was bound by E proteins and contains a cluster of 4 E-box
consensus motifs (CANNTG). Deletion of the 400 bp region containing these 4 sites using
CRISPR/Cas9 genome editing showed that it was required for all expression of Zeb2 in the bone
marrow (BM) and essential for the development of pDC, monocytes, and B cells, suggesting that
these three lineages share similar transcriptional circuitry for their control of Zeb2 expression.
Notably, this enhancer was not required for development of embryonically derived RTMs or for
Zeb2 expression in RTMs but was required for monocyte-derived tissue MF development. Single
cell ATAC-seq identified a second enhancer located 164kb downstream of the Zeb2 TSS that is
selectively active in embryonically derived MF progenitors and RTM arising from transient
definitive hematopoiesis, but not adult definitive hematopoiesis. Thus, the use of the -165-kb
Zeb2 enhancers by cell lineages distinguishes adult and embryonic hematopoiesis.

3.3

Results
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E proteins bind a -165-kb Zeb2 enhancer in both mouse and human.
We previously found a mutually repressive circuit for Zeb2 and Id2 operating during DC
development 37. Since ID2 acts by forming inactive heterodimers with E-proteins, we wondered
whether E-proteins could positively regulate Zeb2 expression. To test this, we examined ChIPseq data for E2-A (encoded by Tcf3) performed in mouse HPC-7 cells 42. This analysis identified
two prominent E2-A-binding peaks in the Zeb2 locus, a peak located 59-kb upstream of Zeb2
TSS (-59-kb Zeb2) and another peak located 165-kb upstream of Zeb2 TSS (-165-kb Zeb2)
(Figure 3.1A). ATAC-seq of hematopoietic lineages showed that the -59-kb Zeb2 enhancer is
active only in HSCs but not in any terminally differentiated lineages tested, suggesting an early
function of this enhancer (Figure 3.1B). The -165-kb Zeb2 enhancer was active in multiple
lineages, including pDCs and monocytes, and its accessibility largely correlated with the level of
Zeb2 gene expression in these lineages 19 (Figure 3.1B).
To test the function of these regions for DC development, we used an in vitro Fms-related
tyrosine kinase ligand (Flt3L) culture system and CRISPR/Cas9 genome editing (Figures 3.1C
and 3.1D). A pair of single guide RNA (sgRNA) flanking each region was introduced by
retroviral vector into CD117hi BM progenitor cells isolated from Cas9 transgenic mice 43,
cultured with Flt3L for seven days and pDC output was analyzed. Targeting the -59-kb Zeb2
enhancer caused no significant changes in pDC output compared to samples with scramble guide
controls, suggesting this enhancer is not required for pDC differentiation from CD117hi
progenitors (Figures 3.1C and 3.1D). However, targeting the -165-kb Zeb2 enhancer caused a
significant reduction in the output of pDCs (Figures 3.1C and 3.1D), suggesting that this region
may be required for Zeb2 expression in CD117hi BM progenitor cells.
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To test whether the -165-kb Zeb2 enhancer binds E-proteins, we performed
electrophoretic mobility shift assay (EMSA) using oligonucleotide probes representing the
sequences flanking each of the four E-box motifs (Figure 3.1E). We used nuclear extracts from
HEK293T cells overexpressing either Tcf3 or gfp and from the WEHI human B cell line, which
expresses high levels of endogenous Tcf3. As a positive control, we used the IgH µE5 enhancer
element known to bind E proteins as an EMSA probe44. E2-A formed strong complexes with the
IgH µE5 probe and with three of the four E-box probes in HEK293T nuclear extracts expressing
Tcf3, but not in extracts expressing only gfp (Figure 3.1E). E2-A also formed complexes with
three of the four E-box probes in nuclear extracts from untransformed WEHI cells, although
weaker than that observed using E2-A overexpression (Figure 3.1E). These results suggest that
the -165-kb Zeb2 enhancer can bind both endogenous and overexpressed E-proteins.
We tested the dependency of -165-kb Zeb2 enhancer activity on E-box motifs using an
integrating retroviral reporter. The enhancer is weakly active in cDC1s, intermediately active in
cDC2s, and highly active in pDCs, mirroring the expression of endogenous Zeb2 (Figure 3.1F
and 3.1G). Consistent with the lack of E protein binding at E box 1 (Figure 3.1E), the deletion of
E box 2-4 but not E box 1 reduced the enhancer activity in pDCs by 2-3 fold. Deletion of all four
E boxes reduced enhancer activity in pDCs by more than fivefold to a level comparable to
cDC1s. Taken together, these data suggest that E box motifs are required for the activity of -165kb Zeb2 enhancer, and E box 2-4 are redundant for each other.
Interestingly, a ChIP-seq for E2-2 performed in human CAL-1 pDC cell line showed
strong E2-2 binding at a site located 183-kb upstream of human ZEB2 TSS, in a 500bp region
that is highly homologues to the mouse -165-kb Zeb2 enhancer region (Figures 3.2A and 3.2D).
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The four E box motifs are conserved between human and mouse and present in similar locations
within each enhancer (Figures 3.2B-D).

-165-kb Zeb2 enhancer is required for Zeb2 expression in vivo in BM.
To analyze the function of -165-kb Zeb2 enhancer in vivo, we generated mice with
germline deletion of this region by electroporating zygotes with Cas9-sgRNA complex (RNP
complex) using the same sgRNA as above (Figure 3.1C). We generated the enhancer deletion in
two genetic backgrounds (Figures 3.3A, 3.4A and 3.4B). First, we used C57BL6/J mice to
produce the Zeb2 –165–/– line, which was then crossed with a reporter mouse line expressing an
Id2-IRES-GFP cassette (Id2gfp) to generate the Zeb2 –165–/–Id2gfp mouse line. We also directly
targeted Zeb2egfp mice 45, harboring a ZEB2-EGFP fusion protein reporter, to produce the
Zeb2egfp –165–/– line.
The BM progenitor cells from these mice were analyzed to test the importance of the 165-kb Zeb2 enhancer on expression of Zeb2 and Id2. Dendritic cell progenitors (DCPs) that
have not specified to the cDC1 lineage are identified as Lin- CD117hi CD135+ CD226- bone
marrow (BM) cells 41. In Zeb2egfp mice, 70% of DCPs expressed high levels of ZEB2-EGFP
(Figures 3.3B and 3.3C), as expected 37. By contrast, Zeb2egfp–165–/– mice have equivalent
numbers of DCPs but fail to express ZEB2-EGFP in either DCPs or in any BM cells. Previously,
conditional deletion of Zeb2 in a Vav-Cre system resulted in neonatal lethality related to
impaired HSC mobility during embryonic development 30. In contrast, we found that Zeb2 –165–
/–

and Zeb2egfp –165–/– mice were born at expected Mendelian ratios, excluding embryonic

lethality, and showed no signs of morbidity. The number of Lin-SCA1+c-KIT+ (LSK)
HSC/progenitor cells was similar between Zeb2 –165–/– mice and Zeb2 –165+/+ mice, but LSK
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cells from Zeb2 egfp –165–/– mice showed no detectable ZEB2-EGFP expression (Figures 3.4CE). These results suggest that the -165-kb Zeb2 enhancer is required for Zeb2 expression in all
HSC-derived lineages but is not required for Zeb2 expression in the progenitors of HSCs during
embryonic development.

-165-kb Zeb2 enhancer deletion increases Id2 expression in BM progenitor cells.
Our genetic analysis indicated that Zeb2 acts downstream of Id2 with respect to cDC1
specification, but acts upstream of Id2 with respect to Id2 expression 37. These results implied
that a mutually repressive circuit between Zeb2 and Id2 is in operation in the CDP whose
outcome determines commitment to either the pDC or cDC1 fate. This model predicts that loss
of Zeb2 expression in CDPs should increase Id2 expression.
To test this, we measured EGFP as a surrogate for Id2 expression in BM progenitors from
Zeb2 –165–/–Id2gfp mice (Figure 3.3D). In total Lin- BM progenitors, there was a substantial
increase in EGFP expression in BM progenitors from Zeb2 –165–/–Id2gfp mice compared to Zeb2
–165+/+Id2gfp control mice, raising the EGFP mean fluorescence intensity (MFI) from 79 to 159.
Also, in the non-specified DCPs fraction, EGFP was increased from 93 MFI in Zeb2 –
165+/+Id2gfp control mice to 309 in Zeb2 –165–/–Id2gfp mice (Figure 3.3D), consistent with the
predicted repression of Id2 by Zeb2.

-165-kb Zeb2 enhancer is required for development of pDCs, monocytes and B cells.
We next examined the impact of the -165-kb Zeb2 enhancer deletion on mature
hematopoietic lineages (Figure 3.5). Evidence suggested that Zeb2 is required for the
development of pDCs 19,20 and monocytes 19, and inducible deletion of Zeb2 in adult mice with
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the Mx1-cre system also resulted in a 5-fold reduction in B cell number in peripheral blood 36.
First, we found a threefold reduction in total splenic cellularity in Zeb2 –165–/– mice compared to
controls (Figure 3.6C). pDCs and monocytes were absent, and B cells were reduced in
percentage by 20-fold in Zeb2 –165–/– mice compared to controls (Figures 3.5A-C and 3.6C). By
contrast, cDC1s and neutrophils were increased as a percentage of splenocytes in Zeb2 –165–/–
mice, but their absolute numbers were relatively unchanged (Figures 3.5A, 3.5C and 3.6C). Red
pulp macrophages (RPMs) were present in normal numbers in Zeb2 –165–/– mice (Figures 3.5C
and 3.6C). T cells and NK cells were increased in Zeb2 –165–/– mice as a percentage of
splenocytes (Figure 3.5B), but not in absolute numbers (Figure 3.6C).
Deletion of the Zeb2 –165–/– enhancer impaired B cell development more severely than
the previously reported deletion of Zeb2 by Mx1-cre 36. We find 20-fold reduction in splenic B
cell percentage, and more than 100-fold reduction by total numbers (Figures 3.5B and 3.6C) in
contrast with the 5-fold reduction reported in Mx1-cre+ Zeb2fl/fl mice. Conceivably, the -165-kb
Zeb2 enhancer is required earlier in development compared with the Mx1-cre induced deletion.
Deletion of theZeb2 –165–/– enhancer did not significantly alter the overall accessibility of
enhancers in the Zeb2 locus in splenic B cells (Figure 3.5D, black dashed boxes indicating
enhancers accessible in both Zeb2 –165–/– and WT B cells). However, the enhancer 164kb
downstream of the Zeb2 TSS become accessible in Zeb2 –165–/– but not in WT B cells,
suggesting a potential site of compensatory enhancer (Figure 3.5D, bottom left panel). The few B
cells that developed in Zeb2 –165–/– mice are similar to WT B cells from Zeb2 –165+/+ mice by
transcriptional profiling (Figure 3.6D), with less than 100 genes differing in expression more
than 4-fold between Zeb2 –165–/– and Zeb2 –165+/+ mice. Zeb2 –165–/– B cells express higher

76

level of Id2 mRNA (Figure 3.6E), in agreement with results from Id2gfp reporter mice (Figure
3.3D).
Since Id2 is required for the development of innate lymphoid cells (ILCs) 46,47, we
quantified NK cells and all three ILC subsets in the small intestine (SI) lamina propria in Zeb2 –
165–/– mice (Figures 3.6A and 3.6B). There were no significant changes in NK cells or ILC3
cells and less than 2-fold increases in ILC1 and ILC2 cells. In summary, the -165-kb Zeb2
enhancer is strictly required for the development of pDCs, monocytes and B cells, but not for
several other hematopoietic lineages.

-165-kb Zeb2 enhancer is required for early lineage specification.
To determine the stage of pDC development impacted by Zeb2 –165–/– enhancer deletion,
we analyzed pDC progenitors in BM (Figures 3.7A and 3.7E). A lymphoid pDC progenitor was
recently identified as a Ly6D+ SiglecH+ double positive (DP) fraction of Lin-CD127+ CD135+
lymphoid progenitors (LPs) 48 (Figure 3.7A). This pDC progenitor comprises 10% of LPs in WT
mice but is completely absent in Zeb2 –165–/– mice (Figures 3.7A and 3.7E). pDCs can also
develop from common dendritic cell progenitor (CDP) but no clonogenic pDC progenitor has
been defined within the CDP. However, cDC1 specification in the CDP (identified as LinCD117int CD117+ CD135+ CD226+ cells 41) was increased by 3-fold in Zeb2 –165–/– mice
compared with WT control mice (Figure 3.7B), suggesting an increase in alternative fate
specification caused by the loss of Zeb2 expression. These results suggest that deletion of the
Zeb2 –165–/– enhancer blocks pDC development at its earliest known stage.
Mx1-cre induced deletion of Zeb2 was reported to arrest B cell development at Hardy
fraction A (Fr. A) 36. In Zeb2 –165–/– mice, Zeb2 expression was lost beginning in HSCs (Figures
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3.4C-E), and we found a significant reduction in all Hardy fractions (Figures 3.7C and 3.7F).
This result suggests that Zeb2 –165–/– mice have a defect in B cell specification from the
common lymphoid progenitor (CLP). Notably, the ILC2 progenitors (ILC2P) that arise from the
CLP 49,50 were also increased in Zeb2 –165–/– mice (Figure 3.7D), suggesting that the CLP is
present but lacks the capacity for B cell specification. Since Id2 is required for development of
NK cells 47,51 and ILCs 52,53, the elevated Id2 expression level in Zeb2 –165–/– mice may deviate
progenitors away from B cell specification in favor of ILC development at the CLP stage.
Id2 reportedly inhibits expression of Csf1r 54, which is required for monocyte
development 55. In agreement, Zeb2 –165–/– mice lacked expression of Csf1r on Lin- CD135+ BM
progenitors (Figure 3.5A), consistent with an effect of increased Id2 expression (Figure 3.3C).
Since Csf1r expression is required to identify the monocyte-dendritic cell progenitor (MDP) 13
and the common monocyte progenitor (cMoP) 56, we were unable to directly evaluate these two
progenitor stages in Zeb2 –165–/– mice (Figure 3.7A). However, the development of cDC1 in
Zeb2 –165–/– mice (Figures 3.5A and 3.6C) suggests that the MDP does develop, since the MDP
gives rise to the CDP in which the cDC1 lineage is specified.

-165-kb Zeb2 enhancer is required for lymphocyte function.
To test whether the few B cells developing in Zeb2 –165–/– mice are functionally normal,
we first investigated their ability to undergo antibody class switch recombination (CSR) in
comparison to WT B cells in an in vitro system. After four days of culture with LPS and IL-4,
Zeb2 –165–/– B cells showed impaired IgG1 surface expression as compared to WT B cells
(Figure 3.8A and 3.8B). Consistent with the defect in B cells function, all Zeb2 –165–/– mice
succumb to West Nile Virus infection after ten days, the clearance of which requires B cells57,
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while 80% of WT animals survived after twenty-two days (Figure 3.8C). Zeb2 –165–/– B cells
also formed fewer and smaller follicles in the spleen than WT B cells (Figure 3.8I). Together,
these data suggest that the -165-kb Zeb2 enhancer is required for B cell functions in vivo. Zeb2
has also been reported to be required for T cell and NK cell function31,32,34. Under steady state,
terminal NK cell maturation was reduced by 7-fold in Zeb2 –165–/– spleen (Figures 3.8D and
3.8E), comparable to previous report using Zeb2fl/fl Ncr1icre mice31. In the context of LCMV-Arm
infection, T cell specific deletion of Zeb2 with either GrzB-cre or CD4-cre significantly reduced
the formation of LCMV-specific Klrg1hi CD127lo terminal effector CD8T cells32,34. Similar
reduction was observed in Zeb2 –165–/– mice as compared to WT mice, eight day after the
inoculation of LCMV-Arm (Figures 3.8F-H). Collectively, these data suggest that the -165-kb
Zeb2 enhancer is required for a wide range of lymphocyte functions.

RTM populations are present in Zeb2 –165–/– mice.
Since splenic RTMs were present in Zeb2 –165–/– mice, we asked whether RTMs were
present in other tissues (Figure 3.9). We found that Zeb2 –165–/– mice had normal populations of
lung alveolar and interstitial MFs, liver Kupffer cells (Figures 3.9A and 3.9B), and peritoneal
cavity macrophages (PCMs) (Figures 3.9C and 3.9D). Consistently, Zeb2 mRNA was expressed
normally in RPM of Zeb2 –165–/– mice compared with control Zeb2 –165+/+ mice (Figure 3.8).
In contrast, Zeb2 mRNA was undetectable in Zeb2 –165–/– BM DCPs (Figure 3.8), consistent
with the lack of EGFP expression by DCPs in Zeb2 egfp –165–/– reporter mice (Figure 3.3A). In
splenic neutrophils and BM pre-DC1 population, where Zeb2 is expressed at a low level in WT
mice, there was more than 5-fold reduction in Zeb2 mRNA levels in Zeb2 –165–/– mice
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compared with WT mice (Figure 3.8). In summary, Zeb2 mRNA expression is maintained in
RTMs, but not in HSC-derived lineages, in Zeb2 –165–/– mice.
Recent work has shown that RTM populations in adult mice are largely of embryonic
origin 15,16,18,58. For example, lineage tracing using Ms4a3-cre suggests that less than 40% of
RPMs are derived from monocytes from the adult HSC 18. To determine the origin of RTMs in
Zeb2 –165–/– mice, we used a model of sterile peritonitis in which intraperitoneal (i.p)
administration of thioglycolate induces the acute loss of peritoneal cavity macrophages (PCM)
18,59,60

. After 72 hours, newly formed PCM are generated from HSC-derived monocytes that

migrate into the peritoneal cavity and differentiate into MFs. We find that at steady state,
untreated Zeb2 –165–/–mice and Zeb2 –165+/+ mice have equivalent numbers of PCM. Further,
thioglycolate treatment i.p. caused complete depletion of PCM in 12 hours in both WT and Zeb2
–165–/– mice. However, after 72 hours, PCM were regenerated in WT mice, but failed to
regenerate in Zeb2 –165–/– mice (Figures 3.9C and 3.9D). These results indicated that steady
state RTM in Zeb2 –165–/– mice are embryonically derived, and that Zeb2 expression in
embryonically derived RTM is not dependent on the -165-kb Zeb2 enhancer.

Embryonic MF development is intact in Zeb2 –165–/– mice.
During transient definitive hematopoiesis, EMPs generate both YS MFs and FL
monocytes in two phases 15. EMPs in the first phase, labeled by Runx1Cre/EYFP lineage tracing at
E7.5, differentiate into YS MFs. A late phase of EMPs, labeled by Runx1Cre/EYFP at E8.5, can
differentiate locally, but can also enter blood circulation and migrate to the FL to differentiate
into monocytes 16.
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To determine if embryonic development of MFs is affected in Zeb2 –165–/– mice, we
examined Zeb2 –165–/– and Zeb2 –165+/+ embryos at E10.5 for YS MFs, and at E15.5 for the
presence and numbers of FL monocytes and MFs. We found no significant change in the
development of YS MFs at E10.5 or FL MFs at E15.5 comparing Zeb2 –165–/– and Zeb2 –165+/+
embryos (Figures 3.9E and 3.9F). FL monocytes were also present at E15.5 in Zeb2 –165–/–
embryos, although slightly reduced in numbers compared to WT embryos (Figures 3.9E and
3.9F). The FL monocytes from Zeb2 –165–/– embryos also expressed Zeb2 at levels similar to
WT embryos (Figures 3.9G and 3.9H). Together, these results indicate that Zeb2 expression
supporting embryonic macrophage and monocyte development during transient definitive
hematopoiesis is independent of the -165-kb Zeb2 enhancer.

Embryonic MF precursors may activate an alternative Zeb2 enhancer.
Since Zeb2 expression during embryonic MF development does not require the -165-kb
Zeb2 enhancer, we wondered if an alternative Zeb2 enhancer may function during embryonic
hematopoiesis. One potential candidate is the +164-kb Zeb2 enhancer that become active in B
cells upon -165-kb Zeb2 enhancer deletion. To test this, we carried out single-cell ATAC-seq 61
on YS MFs isolated from E10.5 WT embryos, FL monocytes isolated from E15.5 WT embryos,
and adult splenic MFs and monocytes from WT mice (Figures 3.11 and 3.12). High quality
scATAC-seq profiles were recovered from 1,484 YS MFs, 6,179 FL monocytes, 8,751 splenic
monocytes, and 6,562 splenic MFs, with a median of 10,554 fragments per cell and a median of
14.3 for enrichment of Tn5 insertions at transcription start sites 61,62. Clustering identified four
major cell clusters representing each cell type, and two minor clusters comprised of mixed cell
types (Table 3.1 and Figure 3.12). The clusters were defined by 37,311 marker peaks and 9,756
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marker gene scores that were consistent with their cellular identities (Figure 3.12). Cluster 1
represented adult RPMs, cluster 2 the YS MFs, cluster 3 the FL monocytes, and cluster 4 the
splenic monocytes.
We next compared the ATAC-seq profile of the four major clusters, focusing on peaks in
the Zeb2 locus (Figure 3.11). An ATAC-seq peak was present in the -165-kb region in splenic
monocytes, as expected, which was also present in each of the other cell types. All other ATACseq peaks present in these other three cell types were also present in adult monocytes, with one
exception. Consistent with our expectation, the +164-kb Zeb2 enhancer and a nearby peak
located at +161-kb, downstream of the Zeb2 TSS were present in RPM, YS MF, and FL
monocytes, but were barely detectable in splenic monocytes. Since RPM in un-manipulated adult
mice are predominantly of fetal origin 16,63, this +164-kb and +161-kb peaks could represent
enhancers sufficient to activate Zeb2 expression in MF progenitors during embryonic
hematopoiesis independent of the -165-kb enhancer. In EMP, the progenitor cells that give rise to
both YS MFs and FL monocytes, ATAC-seq analysis showed significantly activity at both
enhancers64(Figure 3.11). ChIP-seq analysis of histone acetylation at these loci showed that the
+164-kb region is heavily acetylated in embryonically derived Kupffer cells but not in BM
derived adult monocyte, indicating the embryonic specific activity of this enhancer65 (Figure
3.11). Consistently, in a retroviral reporter system, the +164-kb Zeb2 enhancer showed higher
activity than that of the -165-kb Zeb2 enhancer in YS derived macrophages. The activity of the
+164-kb Zeb2 enhancer in YS derived macrophages is also higher than that of the adult BM
derived monocytes (Figure 3.10B), while the +161-kb region showed no activity in any
populations. Since there are distinct TF motifs used by the different cell types (Figure 3.12C), the
+164-kb region may conceivably bind TFs that are active during embryonic hematopoiesis but
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are not active in adult HSCs. In particular two Nur77 motifs are present in the +164-kb enhancer
but not the +161kb or the -165kb enhancers (Figure 3.6F), and notably, the transcription factor
NUR77 (encoded by Nr4a1) is highly expressed in YS MFs and FL monocytes but not adult
BM-derived monocytes66 (Figure 3.10C), and ChIP-seq analysis of NUR77 in RAW macrophage
cell line showed strong binding at the +164-kb Zeb2 enhancer 67(Figure 3.11), two HOMER
predicted NUR77 motifs are also present in the +164-kb region (Figure 3.6C). Consistently,
NUR77 deficient (Nr4a1–/–) embryos showed significantly reduced FL monocytes and
macrophage production (Figure 3.10D). Take together these results suggest a potential role of
Nur77 in supporting Zeb2 expression at the +164-kb Zeb2 enhancers in fetal macrophage
progenitors (Figure 3.10F). In this way, adult hematopoiesis would be uniquely dependent the 165-kb enhancer. Testing this concept will require the specific mutations of the +164-kb region
and assaying its role in embryonic and adult MF development.

3.4

Discussion
A role for ZEB2 in pDC, B cell and monocyte development was previously shown using

deletion of its coding regions, but previous studies did not address the mechanism controlling
Zeb2 expression in these three distinct lineages. E2A is the predominant E protein in B cells,
while E2-2 is predominant in pDCs, suggesting that both of these lineages could maintain Zeb2
expression via the -165-kb enhancer using these factors. However, neither of these E proteins is
highly expressed in monocytes, which instead express PU.1. Conceivably, monocyte progenitors
such as the MDP use an E protein to activate Zeb2 expression via the -165-kb enhancer, which
may be maintained subsequently by another factor such as PU.1. In agreement, E2A is highly
and uniformly expressed in the MDP 41. Alternately, PU.1 expressed in the MDP could initiate
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the activity of the -165-kb enhancer, since there is a consensus motif (GAGGGA) sequence
capable of binding PU.1 that partially overlaps the first E-box motif. Subsequent Zeb2
expression could then be maintained by either E2A or E2-2 after pDC and B cell specification.
Testing these possibilities will require the generation of additional germline mutations within the
-165-kb enhancer.
The present study also investigated the molecular mechanisms governing the expression
of Zeb2 throughout hematopoiesis and highlights the differential usage of enhancers of the same
gene by lineages arising from different stages of hematopoiesis. A recent study, assaying Irf8
enhancers during cDC1 development, has discovered how different enhancers of the same gene
can be required at different stages during the development of a single lineage 41. Although the
development of cDC1 requires both the +41-kb and +32-kb Irf8 enhancer, it was demonstrated
that the +41-kb Irf8 enhancer is required for the specification of CDPs to pre-cDC1s, while the
+32-kb Irf8 enhancer is essential for commitment of pre-cDC1s to mature cDC1s. Our study
expands that discovery by examining the usage of Zeb2 enhancers throughout hematopoiesis.
While all HSC-derived lineages that emerged during adult hematopoiesis are dependent on -165kb Zeb2 enhancer for Zeb2 expression, RTMs and their embryonic precursors express normal
levels of Zeb2 despite the absence of this enhancer. Instead, these cells, arising from embryonic
hematopoiesis might rely on a +164-kb Zeb2 enhancer to maintain their ZEB2 level. These
stage-specific activities of enhancers to differentially regulate the expression of a single gene
could also exist for other genes important during hematopoiesis. The analysis of such activities
could reveal molecular mechanisms that regulate early hematopoiesis that are not yet fully
understood.
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RTMs from embryonic and BM origin have been shown to have different gene
expression profiles 65,68, reflecting their differences in functions and self-maintenance. Other
reports have demonstrated that monocyte-derived MFs can acquire almost identical
transcriptional signatures in tissues as embryonically derived MFs, arguing that tissue-specific
cues rather than ontogenies are more dominant in imprinting MF transcriptional programs 21,69.
The Zeb2 –165–/– mouse provides a unique model to interrogate these two models since only
embryonically derived MFs are present. These mice allow for the examination of functions of
MFs derived from different sources by comparing the responses of these mice with control mice
containing normal BM-derived MFs to various infection models where MFs play a key role.
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Figure 3.1. E proteins engage the –165–kb Zeb2 enhancer to regulate Zeb2 expression.
(A) Normalized sequencing tracks of ChIP–seq with anti–CTCF or anti–TCF3 in mouse HPC–7
cell line (mm9) 42 or of placental mammal basewise conservation from PhyloP70. The –59–kb
and –165–kb Zeb2 enhancers are shown as boxed (n = 1 biological replicate per population). (B)
Normalized sequencing tracks of ATAC–seq in the indicated populations. The –59–kb and –
165–kb Zeb2 enhancers are shown as boxed, the +164-kb Zeb2 enhancer is indicated with a red
triangle at the bottom of the track (adapted from Immunological Genome Project Open
Chromatin Regions, n = 1 biological replicate per population). (C and D) BM progenitor cells
(Lin– CD117hi) isolated from Cas–9 transgenic mouse expressing a pair of sgRNA targeting the –
59–kb or –165–kb Zeb2 enhancers or scramble controls were cultured with Flt3L for 7 days and
analyzed by flow cytometry to identify DC subsets. (C) Numbers indicate the percentage of cells
in the indicated gates (representing four independent experiments, n=4 for all sgRNA pairs). (D)
Statistical analysis of the frequency of pDCs from the cultures in C, small horizontal lines
indicate the mean (representing four independent experiments, n=4 for all sgRNA pairs). (E)
Electrophoretic mobility shift assay (EMSA) of E2–A DNA binding activity with indicated
probes and nuclear extracts from WEHI cells or HEK293–T cells overexpressing GFP or Tcf3.
(F) Flow cytometry analysis showing GFP-reporter activities in BM-derived cDC1s, cDC2s, and
pDCs infected with empty retrovirus (black) or retroviruses expressing WT or mutant –165–kb
Zeb2 enhancer as indicated. 4 mut, –165–kb Zeb2 enhancer with all 4 E boxes deleted. E1–E4
mut, 165–kb Zeb2 enhancer with E box 1-4 deleted respectively. (G) Statistical analysis of GFP
MFI in indicated cell types in F. Small horizontal lines indicate the mean (representing three
independent experiments, n=3 for each population) *P < 0.05; **P < 0.01, unpaired, two–tailed,
Student’s t–test.
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Figure 3.2. E proteins bind -165-kb Zeb2 enhancer in both mouse and human.
(A) Normalized sequencing tracks of ChIP–seq with anti–E2-2 or input control in human CAL-1
pDC cell line (hg19) 71 or of placental mammal basewise conservation from PhyloP 70. (B)
Consensus mouse E-box motif from Homer. (C) FImonocyte analysis depicting p-values of
predicted E-boxes in human Zeb2. (D) Alignment of human, genome draft hg19, and mouse,
genome draft mm10, for the –165–kb Zeb2 enhancer regions. Red boxes indicate E-boxes motif
in mouse.
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Figure 3.3. Deletion of the –165kb Zeb2 enhancer eliminates Zeb2 expression and increase
Id2 expression in BM progenitor cells.
(A) Schematics showing the –165kb Zeb2 enhancer with four E–box motifs and sgRNA target
sequences depicted (left) and strategies of generating the Zeb2 –165–/–, Zeb2egfp –165–/–, and Zeb2
–165–/–Id2gfp mice lines (right). (B) Flow cytometry analyzing BM progenitor cells from mice of
the indicated genotype to identify lineage negative progenitors and dendritic cell progenitors
(DCP). Lineage markers include: CD3, CD105, and Ter119. Numbers indicate the percentage of
cells in the indicated gates (representing four independent experiments, n=4 for Zeb2 –165+/+ and
Zeb2 –165–/– mice). (C and D) Flow cytometry analyzing BM cells from Zeb2egfp –165–/– and
Zeb2 –165–/–Id2gfpmice for GFP expression in populations as gated in (B). Numbers indicate the
geometric mean fluorescence intensity (MFI) of GFP in the indicated populations (representing
four independent experiments n=4 for Zeb2egfp –165+/+ and Zeb2egfp –165–/– mice and n=1 for
Zeb2 –165–/–Id2gfpmice). (C) Statistical analysis of percentage of GFP+ cells in the indicated
populations (middle panel), and of MFI of the indicated populations (right panel). Small
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horizontal lines indicate the mean (representing four independent experiments n=4 for Zeb2egfp –
165+/+ and Zeb2egfp –165–/– mice). ***P < 0.001; ****P < 0.0001, unpaired, two–tailed,
Student’s t–test.
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Figure 3.4. Deletion of -165-kb Zeb2 enhancer do not affect LSK cell development but
eliminate Zeb2 expression in this population.
(A) PCR of the -165-kb locus in wildtype (WT), Zeb2 –165–/–, and Zeb2egfp –165–/– mice
demonstrating the deletions induced by CRISPR/Cas9 genome editing. WT band, 860 base pair
(bp). Zeb2 –165–/– band, 496 bp. Zeb2egfp –165–/– band, 492 bp. (B) Nucleotide sequence of the 165-kb Zeb2 enhancer region. The extent of deletion in the two mouse strains are indicated by
color. Blue nucleotides were deleted only in Zeb2egfp –165–/– mice, red nucleotides were deleted
in both strains. (C and D) Flow cytometry analyzing BM cells from Zeb2egfp –165+/+ and
Zeb2egfp –165–/– mice to (C) identify LSK cells, and (D) their GFP expression (representing three
independent experiments n=3 for Zeb2egfp –165+/+ and Zeb2egfp –165–/– mice). (E) Statistical
analysis of MFI of LSK cells (left panel), of percentage of GFP+ cells in LSK cells (middle
panel), and of LSK cells as a percentage of Lin- cells (right panel). Small horizontal lines
indicate the mean (representing three independent experiments n=3 for Zeb2egfp –165+/+ and
Zeb2egfp –165–/– mice). N.S. not significant; **P < 0.01, unpaired, two–tailed, Student’s t–test.
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Figure 3.5. Zeb2 –165kb enhancer is required for pDC, B cell and monocyte development.
(A–C), Flow cytometry analysis of (A, left panel) pDCs and cDC1s, (B, left panel) B cells, T
cells, and NK cells, and (C, left panel) neutrophils (neutro), monocytes (MO) and red pulp
macrophages (RPM) in spleen of mice of indicated genotypes. Statistical analysis of these
lineages as percentage of total splenocytes (A-C, right panels). Small horizontal lines indicate the
mean (representing three independent experiments, n=4–8 for each lineage analyzed). (D)
Normalized sequencing tracks of ATAC–seq in the Zeb2 –165+/+ and Zeb2 –165–/– splenic B
cells and normalized sequencing tracks of ChIP–seq with anti–TCF3 in mouse HPC–7 cell line
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(mm10) 42. The +161–kb, +164–kb, and –165–kb Zeb2 enhancers are shown as boxed. (n = 2-3
biological replicates per population). N.S. not significant; *P < 0.05; ****P < 0.0001, unpaired,
two–tailed, Student’s t–test.
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Figure 3.6. Hematopoietic lineage development in Zeb2 –165–/– mice.
(A) Flow cytometry of cells in small intestines (SI) from Zeb2 –165+/+ and Zeb2 –165–/– mice to
identify ILC populations (representing three independent experiments n=3 for Zeb2 –165+/+ and
Zeb2 –165–/– mice). (B) Statistical analysis of populations identified in (A) as a percentage of
Lin- CD45+ cells. Lineage markers include: CD3, CD5, and CD19 (representing three
independent experiments n=3 for Zeb2 –165+/+ and Zeb2 –165–/– mice). (C) Statistical analysis
of the absolute numbers of indicated populations in spleens (representing three independent
experiments n=3-6 for Zeb2 –165+/+ and Zeb2 –165–/– mice). (D and E), Microarray analysis of
splenic B cells isolated from Zeb2 –165+/+ and Zeb2 –165–/– mice. (D), Scatter plots shown are
comparisons between Zeb2 –165+/+ and Zeb2 –165–/– splenic B cells (upper panel) or between
Zeb2 –165+/+ splenic B cells and cDC1s (lower panel)37. (E), Heatmap showing expression of
genes that are at least four fold differentially expressed between Zeb2 –165+/+ and Zeb2 –165–/–
B cells. Data were average of three independent experiments. (F) Schematics showing the +161–
kb, +164–kb, and –165–kb Zeb2 enhancers and transcription factor motifs predicted by HOMER
(ver 4.9). N.S. not significant; *P < 0.05; **P < 0.01; ****P < 0.0001, unpaired, two–tailed,
Student’s t–test.
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Figure 3.7. Zeb2 –165kb enhancer is required for BM pDC and B cell progenitors.
(A-D), Flow cytometry of BM cells from Zeb2 –165+/+ and Zeb2 –165–/– mice to identify (A)
double positive lymphoid progenitors (DP LPs), (B) pre–cDC1, (C) Hardy fraction A–C, or (D)
ILC–2 progenitor (ILC2P). Lineage markers include: CD3, CD105, and Ter119. Numbers
indicate the percentage of cells in the indicated gates (representing three independent
experiments, n=3 for Zeb2 –165+/+ mice, n=6 for Zeb2 –165–/– mice). (E and F) Statistical
analysis (E) of populations analyzed in (A) and (B), or (F) of population analyzed in (C) and (D)
as percentage of Lin– BM cells (representing three independent experiments, n=3 for Zeb2 –
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165+/+ mice, n=6 for Zeb2 –165–/– mice). **P < 0.01; ***P < 0.001; ****P < 0.0001, unpaired,
two–tailed, Student’s t–test.
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Figure 3.8. Zeb2 –165kb enhancer is required for lymphocyte functions in vivo.
(A) Flow cytometry analysis of sorted Zeb2 –165+/+ and Zeb2 –165–/– splenic B cells cultured
with LPS or LPS + IL-4. (representing three independent experiments n=3 for Zeb2 –165+/+ and
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Zeb2 –165–/– mice ). (B) Statistical analysis of IgG1+ B cells in (A) as percentage of total
cultured B cells. (representing three independent experiments n=3 for Zeb2 –165+/+ and Zeb2 –
165–/– mice ). N.S. not significant; *P < 0.05; **P < 0.01; ****P < 0.0001, unpaired, two–
tailed, Student’s t–test. (C) Combined survival data from WNV infected Zeb2 –165+/+ and Zeb2
–165–/– mice (n=10 for Zeb2 –165+/+ and n=5 for Zeb2 –165–/– mice). ***P < 0.001, GehanBreslow-Wilcoxon test. (D) Flow cytometry analysis of NK cells in the spleen of Zeb2 –165+/+
and Zeb2 –165–/– mice. Cells in the red gate in the left panel are shown in the middle and right
panels. (representing three independent experiments n=3 for Zeb2 –165+/+ and Zeb2 –165–/– mice
). (E) Statistical analysis of the indicated NK cell population in (D) as a percentage of total
NK1.1+ splenocytes. (F) Flow cytometry analysis of GP33 tetramer+ CD8+ T cells in the spleen
of LCMV infected Zeb2 –165+/+ and Zeb2 –165–/– mice (representing three independent
experiments n=3 for Zeb2 –165+/+ and Zeb2 –165–/– mice ). (G) Statistical analysis of absolute
numbers of indicated populations in spleens (representing three independent experiments n=3-6
for Zeb2 –165+/+ and Zeb2 –165–/– mice). (H) Statistical analysis of indicated population in (F) as
percentages of total splenocytes (representing three independent experiments n=3-6 for Zeb2 –
165+/+ and Zeb2 –165–/– mice). (I) Immunohistological H&E staining of spleens from Zeb2 –
165+/+ and Zeb2 –165–/– mice. N.S. not significant; **P < 0.01; ***P < 0.001; ****P < 0.0001,
unpaired, two–tailed, Student’s t–test.
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Figure 3.9. RTM development is intact in Zeb2 –165kb enhancer deletion mice.
(A) Flow cytometry of the indicated tissues from Zeb2 –165+/+ and Zeb2 –165–/– mice to identify
MF populations (representing four independent experiments, cells on the lower panel were pregated on CD64 and F4/80 double positive, n=4 for Zeb2 –165+/+ and Zeb2 –165–/– mice). (B)
Statistical analysis of populations in (A) as percentage of CD45+ cells. (C) Flow cytometry
analyzing peritoneal cavity macrophage (PCM) populations as a percentage of CD45+ cells from
Zeb2 –165+/+ and Zeb2 –165–/– mice with indicated treatments (representing three independent
experiments, n=3-7 for Zeb2 –165+/+ and Zeb2 –165–/– mice). (D) Statistical analysis of
populations in (C) as percentage of CD45+ cells. (E) Flow cytometry of the indicated tissues at
the indicated time from Zeb2 –165+/+ and Zeb2 –165–/– embryos to identify MF and monocyte
(MO) populations (representing three independent experiments, n=3–5 for Zeb2 –165+/+ and
Zeb2 –165–/– mice). (F) Statistical analysis of populations in (E) as percentage of CD45+ cells.
(G) Flow cytometry analyzing ZEB2 level by EGFP expression in fetal liver monocytes (MO)
from Zeb2egfp –165+/+ and Zeb2egfp –165–/– mice. Numbers indicate the geometric mean
fluorescence intensity (MFI) of GFP in the indicated populations (representing three independent
experiments n=3 for Zeb2egfp –165+/+ and Zeb2egfp –165–/– mice). (H) Statistical analysis of MFI
of fetal liver monocytes in G. Small horizontal lines indicate the mean (representing three
independent experiments n=3 for Zeb2egfp –165+/+ and Zeb2egfp –165–/– fetuses). N.S. not
significant; **P < 0.01, unpaired, two–tailed, Student’s t–test.

102

Figure 3.10. Zeb2 expression in RPM is not affected by deletion of -165-kb Zeb2 enhancer.
(A) Statistical analysis of normalized Zeb2 expression by mRNA in the indicated population
(representing three independent experiments, n=3 for all samples). (B) Statistical analysis of MFI
of GFP-reporter activities in BM-derived monocytes, macrophages and YS-MF-derived
macrophages infected with empty retrovirus (black) or retroviruses expressing indicated Zeb2
enhancers. Small horizontal lines indicate the mean (representing three independent experiments,
n=3 for each population). (C) Heatmap showing expression of genes that are at least two fold
differentially expressed between FL MOs and BM MOs by microarray analysis66. Data were
average of four independent experiments. (D) Statistical analysis of indicated populations from
WT, Zeb2 –165–/–, or Nr4a1–/– mice as percentage of CD45+ cells. Nur, Nr4a1–/– mice. N.S. not
significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, unpaired, two–tailed,
Student’s t–test.
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Figure 3.11. Embryonic MF precursors engage a +164kb Zeb2 enhancer to regulate Zeb2
expression.
Normalized pseudo-bulk ATAC-seq tracks in the indicated lineages from the indicated clusters,
bulk ATAC-seq of EMP64 and ChIP-seq tracks of indicated histone marks or transcription factor
in indicated lineages. The +161–kb and +164–kb (dashed line) and –165–kb (solid red line) Zeb2
enhancers are shown as boxed (representing one biological replicate for ATAC-seq and 2-3
replicates for ChIP-seq).
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Figure 3.12. Epigenetic landscape of clusters identified from scATAC-seq.
(A) UMAP projection of 22,976 scATAC-seq profiles of indicated populations. Dots represent
single cells and are colored based on their identity (upper panel) or their cluster (lower panel).
(B) Heatmap depicting cluster average Z-score of marker peaks for each cluster. (C) Heatmap
depicting TF binding motifs that are enriched for each cluster within the marker peaks in (B). (D)
Heatmap depicting cluster average Z-score of marker protein-coding genes for each cluster.
Marker genes are computed using ArchR62 Gene Scores. (E) Composition of cell types within
each cluster (labels as in A, lower panel). Bars are colored based on their identity (A, upper
panel). (F and G) Normalized pseudo-bulk ATAC-seq tracks of the indicated populations. The
+161–kb, +164-kb (dashed line) and –165–kb (solid red line) Zeb2 enhancers are shown as
boxed (representing one biological replicate).
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Table 3.1 Numbers of cells from each lineage in clusters identified in sc-ATAC-seq.

Cluster 1

Cluster 2

Cluster 3

Cluster 4

Cluster 5

Cluster 6

Total

FL MO

2

136

5975

58

5

3

6179

RPM

5058

90

9

402

926

77

6562

Sp MO

2

71

83

7367

686

542

8751

YS MF

3

1447

33

1

0

0

1484

107

3.5

Materials and Methods

Mice
WT C57BL6/J mice and R26Cas9/+ mice (B6N.129(Cg)-Gt(ROSA)26Sortm1.1(CAG-cas9*,EGFP)Fezh

/J) were obtained from the Jackson Laboratory. ZEB2-EGFP fusion protein reporter

(STOCK Zfhxlbtm2.1Yhi) mice were derived from biological material provided by the RIKEN
BioResource Center through the National BioResource Project of the Ministry of Education,
Culture, Sports, Science and Technology, Japan. Id2–IRES–GFP mice72 were generously
donated by G. Belz.
All mice were generated, bred, and maintained in the Washington University in St. Louis
School of Medicine specific pathogen-free animal facility. Animals were housed in individually
ventilated cages covered with autoclaved bedding and provided with nesting material for
environmental enrichment. Up to five mice were housed per cage. Cages were changed once a
week, and irradiated food and water in autoclaved bottles were provided ad libitum. Animal
manipulation was performed using standard protective procedures, including filtered air
exchange systems, chlorine-based disinfection, and personnel protective equipment including
gloves, gowns, shoe covers, face masks, and head caps. All animal studies followed institutional
guidelines with protocols approved by the Animal Studies Committee at Washington University
in St. Louis.
Unless otherwise specified, experiments were performed with mice between 6 and 10
weeks of age. No differences were observed between male and female mice in any assays
performed and so mice of both genders were used interchangeably throughout this study. Within
individual experiments, mice used were age- and sex-matched whenever possible.
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Generation of Zeb2 enhancer deletion mice
Enhancer deletion mice were generated as described 41. sgRNAs flanking the -165-kb
Zeb2 enhancer were identified using CHOPCHOP (http://chopchop.cbu.uib.no/), and the
following sgRNA sequences were used: Zeb2 -165 5’: GAGTGAGAGATCATCAAATG and
Zeb2 +165 3’: GATAACGTTCTTGAAGCATA. sgRNA with the desired sequences were
synthesized and conjugated with purified Cas9 protein to form the RNP complex by the
Department of Pathology Micro-Injection Core at Washington University in St Louis. Day 0.5
single cell zygotes from C57Bl/6 mice were isolated and underwent electroporation at the
Department of Pathology Micro-Injection Core at Washington University in St Louis. Around 60
single cell zygotes were electroporated with 8µM of RNP complex using 1mm gap cuvette
(BioRad). Electroporated zygotes were then transferred into the oviducts of pseudopregnant
recipient mice.
The resulting pups were screened by PCR with the following primers to identify those
that had successful deletion of the enhancers of interest: 165KO-Screening-5’:
CTGCAGCAGGTTGACAAAGA; 165KO-Screening-3’: CCTGAAGTGTACGCTCACCA.
Mice with the desired deletion were then outcrossed to wildtype (WT) C57BL6/J mice, and the
resulting heterozygous mice were intercrossed to generate homozygous enhancer deletion mice.

Antibodies and flow cytometry
Cells were kept at 4ºC while being stained in PBS supplemented with 0.5% BSA and
2mM EDTA in the presence of antibody blocking CD16/32 (2.4G2; BD).
The following antibodies were from BD: Brilliant Ultraviolet 395–anti-CD117 (2B8),
PE-CF594–anti-CD135 (A2F10.1), V500–anti-MHC-II (M5/114.15.2), Alexa Fluor 700 or
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allophycocyanin–anti-Ly6C (AL-21), Brilliant Violet 421–anti-CD127 (SB/199), biotin or
FITC–anti-CD19 (1D3), Brilliant Violet 421–anti-CCR9 (CW-1.2), allophycocyanin –anti-CD43
(S7), PE mouse anti-mouse CD249 (Lγ-51) (BP-1), PE–anti-NK1.1 (PK136), PE–anti-Ly6G
(1A8). The following antibodies were from eBioscience: PE-Cy7–anti-TCRβ (H57-597),
allophycocyanin–eFluor 780–anti-CD11c (N418), violetFluor 450–anti-MHC Class II (I-A/I-E)
(M5/114.15.2), eFluor 450–anti-CD11b (M1/70), allophycocyanin–anti-CD317 (eBio927),
peridinin chlorophyll protein (PerCP)–eFluor 710–anti-CD172a (P84), PerCP-Cy5.5–antiSiglecH (eBio-440c), PE–anti-IL-25R (MUNC33), APC-eFluor 780-anti-F4/80 (BM8), biotin–
anti-CD105 (MJ/718), PE-Cy7–anti-CD25 (PC61.5).The following antibodies were from
BioLegend: PE–anti-Ly6D (49-H4), PE-Cy7–anti-CD24 (M1/69), Brilliant Violet 711–antiCD115 (AFS98), PE or Brilliant Violet 421–anti-XCR1 (ZET), PE–anti-CD45.2 (104),
PE/Dazzle 594–anti-CD45R (RA3-6B2), biotin–anti-Ly6G (1A8), biotin–anti-Ter119 (TER119), PE–anti-CD226 (10E5), Brilliant Violet 605–anti-CD64 (X54-5/7.1), biotin or APC–antiCD3e (145-2c11). Cells were analyzed on a FACSCanto II or FACSAria Fusion flow cytometer
(BD), and data were analyzed with FlowJo v10 software (TreeStar).

BM progenitor analysis
Bone marrow (BM) was harvested as described 73. For FACS analysis, BM cells was
isolated and depleted of CD3-, CD105-, Ter119- and in the instance of HSC analysis CD19- and
Ly6G-expressing cells by staining with corresponding biotinylated antibodies followed by
depletion with MagniSort Streptavidin Negative Selection Beads (Thermo Fisher). All remaining
BM cells were then stained with fluorescent antibodies prior to sorting.
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Tissue harvest and population analysis
Tissues were harvested as described41. Briefly, spleens were minced and digested in 5 ml
of Iscove’s modified Dulbecco’s media (IMDM) + 10% FCS (cIMDM) with 250 μg/ml of
collagenase B (Roche) and 30 U/ml of DNaseI (Sigma-Aldrich) for 45 min at 37 °C with stirring.
Lungs were minced and digested in 5 ml of cIMDM with 4 mg/ml of collagenase D (Roche) and
30 U/ml of DNaseI (Sigma-Aldrich) for 1.5 h at 37 °C with stirring. Livers were minced and
digested in 5 ml of cIMDM with 125µg/ml of Liberase TL (Roche) and 30 U/ml of DNaseI
(Sigma-Aldrich) for 1h at 37 °C with stirring. After digestion was complete, single-cell
suspensions from all organs were passed through 70-μm strainers and red blood cells were lysed
with ammonium chloride–potassium bicarbonate (ACK) lysis buffer. Cells were subsequently
counted with a Vi-CELL analyzer (Beckman Coulter) and 3-5 × 106 cells were used per antibody
staining reaction.
For peritoneal cell analysis, 5 ml of MACS buffer (Dulbecco’s phosphatebuffered saline
+ 0.5% BSA +2 mM ethylenediaminetetraacetic acid (EDTA)) was injected into the peritoneum
of mice using a 27-g needle. After injection, the mice were shaken gently to dislodge peritoneal
cells. A 25-g needle was then used to collect the peritoneal fluid. Cells were lysed with ACK
buffer and counted as described above.
For small intestine analysis, small intestines were collected and flushed with HBSS to
remove the fecal contents. Peyer’s patches were removed, intestines were openned lengthwise,
washed and cut into small pieces. Cut pieces were subjected to gentle agitation for 20 mins in a
solution containing HBSS, HEPES, BCS and EDTA and then vortexed. This agitation step was
repeated once more. Tissues pieces were then rinsed in HBSS before being digested with
collagenase type IV in complete RPMI medium for 40-45 minutes at 37oC with gentle shaking.
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Digests were filtered, centrifuged, and subjected to density gradient centrifugation using 40%
and 70% percoll solutions. Cells from the interface were recovered, washed and used for
analysis.

Yolk sac and fetal liver harvest and population analysis
Yolk sacs were harvested from embryos at E10.5 and digested in 1ml of MACS buffer
with 250 μg/ml of collagenase B (Roche) and 30 U/ml of DNaseI (Sigma-Aldrich) for 30 min at
37 °C with stirring. Fetal liver was harvested from embryos at E15.5 and mechanically
dissociated by passing through a 20-g needle three times. The single cell suspensions were then
filtered and cells were lysed with ACK buffer as described above. For YS macrophage culture,
the YS macrophages were sorted and then cultured with 25ng/ml MCSF and the culture was
analyzed after four days.

Thioglycollate induced sterile peritonitis
The sterile peritonitis was induced as described 18. Briefly, 1 mL of 4% sterile
thioglycollate broth (BD Biosciences) was injected i.p. into 8-week-old mice of the indicated
genotypes and then analyzed at the indicated time points.

Expression microarray analysis
RNA from Zeb2 –165+/+ and Zeb2 –165–/– B cells was extracted with a NucleoSpin RNA
XS Kit (Machery-Nagel), amplified with WT Pico System (Affymetrix) and hybridized to
GeneChip Mouse Gene 1.0 ST microarrays (Affymetrix) for 18 h at 45 °C in a GeneChip
Hybridization Oven 640. The data was analyzed with the Affymetrix GeneChip Command
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Console. Microarray expression data was processed using Command Console (Affymetrix, Inc)
and the raw (.CEL) files generated were analyzed using Expression Console software with
Affymetrix default RMA Gene analysis settings (Affymetrix, Inc). Probe summarization
(Robust Multichip Analysis, RMA), quality control analysis, and probe annotation were
performed according to recommended guidelines (Expression Console Software, Affymetrix,
Inc.). Data were normalized by robust multiarray average summarization and underwent quartile
normalization with ArrayStar software (DNASTAR).

Quantitative RT-PCR (qPCR)
RNA from indicated populations from Zeb2 –165+/+ and Zeb2 –165–/– was extracted with
a NucleoSpin RNA XS Kit (Machery-Nagel). cDNA was generated using SuperScript IV OneStep RT-PCR system (Invitrogen) and Oligo(dT)20 Primer (Invitrogen). qPCR was performed
using SYBR Green-based detection and the following previously published primers20: Zeb2qPCR-F: GGCAAGGCCTTCAAGTACAA; Zeb2-qPCR-R: AAGCGTTTCTTGCAGTTTGG;
GAPDH-qPCR-F: TGCCCCCATGTTTGTGATG; GAPDH-qPCR-R:
TGTGGTCATGAGCCCTTCC. The amount of Zeb2 mRNA detected from each sample was
normalized to that of GAPDH mRNA.

Retroviral infection and culture
Retroviruses were produced by transfecting retroviral vectors into Plat-E cells essentially
as described 37 and collecting viral supernatants 2 days later. For in vitro CRISPR/Cas9 deletion,
a Thy1.1-hU6-gRNA-BbsI stuffer RV vector and a GFP-hU6-gRNA-BbsI stuffer RV vector
were used 74 . The following primers containing the sgRNA sequence and BbsI overhangs were
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annealed and cloned into the BbsI digested vector, all 5' oligonucleotides were cloned into the
Thy1.1 vector and all 3' oligonucleotides were cloned into the GFP vector. For the Zeb2 -165-kb
5’ sgRNA: CACCGgagtgagagatcatcaaatg and AAACcatttgatgatctctcactcC. For the Zeb2 -165-kb
3’ sgRNA: CACCGgataacgttcttgaagcata and AAACtatgcttcaagaacgttatcC. For the Zeb2 -59-kb
5’ sgRNA: CACCGtcaatgtgcaaataccacga and AAACtcgtggtatttgcacattgaC. For Zeb2 -59-kb 3’
sgRNA: CACCGgccatttcctgcactcagga and AAACtcctgagtgcaggaaatggcC. Lin— CD117hi BM
cells from R26Cas9/+ mice were then sorted and transduced with viral supernatants by spin
infection at 1800 RPM for 1 hour in the presence of 2 ug/mL polybrene. Infected cells were then
cultured in Flt3L for 8 days before DCs were analyzed by flow cytometry. For in vitro reporter
assay, a Thy1.1 pA GFP CMVp_min PmeI MSCV vector was used as control, enhancer
elements were cloned into this vector to test their activity in vitro. Lin— CD117hi BM cells and
YS macrophages from WT mice were sort purified and and transduced with viral supernatants by
spin infection at 1800 RPM for 1 hour in the presence of 2 ug/mL polybrene. Infected cells were
then cultured in Flt3L for 8 days or MCSF for 4 days before GFP activities were analyzed by
flow cytometry.

Electrophoretic mobility shift assay (EMSA)
EMSAs were performed as described 75. Oligonucleotide pairs were annealed to generate
probes that were labeled with 32P-dCTP using Klenow polymerase. HEK293FT cells were
transiently transfected with retroviral vectors for Tcf4 or GFP using TransIT-LT1. After 48 h,
cells were lysed with buffer A (10 mM HEPES-KOH, pH 7.9, 1.5 mM MgCl2 and 10 mM KCl)
containing 0.2% NP40 and protease inhibitors. Nuclei were pelleted, resuspended in buffer C (20
mM HEPES-KOH, pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA and 25% glycerol),
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and centrifuged to obtain nuclear extracts 76. EMSA was performed using nuclear extracts from
HEK293T cells transfected with Tcf4 or GFP (up to 1.5 μg total) or Wehi cells, 0.25 μg poly dIdC (Sigma) and 32P-labeled probes in 10 μl binding reactions for 20 min at 4 °C. Reactions were
separated on 4–7%T 3.3%C polyacrylamide mini-gels in 0.4× TBE for 50 min at 250 V and 4 °C
and were analyzed by autoradiography.

B cell class switching recombination assay
Splenic B cells were sort purified from and cultured at the density of 500,000 cells/ml in
96 well plate with either LPS (10µg/ml, Sigma-Aldrich) alone, or LPS (10µg/ml) and IL-4
(25ng/ml, Peprotech). Cells were collected on day 4, and surface IgG1 expression was analyzed
by FACS.

Analysis of E-box motifs in human -165-kb Zeb2 enhancer
The occurrence of E-box motifs in the element -165-kb relative to the Zeb2 transcription
start site was found with the FIMO motif-identification program 77 at a P-value threshold of 1 ×
10−2 with the E-box position weight matrix obtained from Homer software packge78. Human and
mouse elements were aligned via Clustal Omega W.

Bulk ATAC-seq
Bulk atac-seq samples were processed according to the previously described OmniATAC protocol79. Briefly, cells were thawed, live/dead stained, and sorted for viability. Sorted
cells were lysed and then nuclei were transposed for 30 minutes. For samples with less than
50,000 live cells recovered, the amount of Tn5 enzyme was scaled down according to the cell
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number, but the transposition reaction volume was maintained at 50 uL. Transposed fragments
were then amplified and prepared for sequencing. Samples were quantified by bioanalyzer and
2x75 paired end sequencing was performed using an Illumina Nextseq.

Viral infections
For LCMV infection, mice were infected with 2 x 105 plaque-forming units (PFU) of
LCMV-Arm strain via the intraperitoneal route. Splenic T cells were harvested on day 8 after
infection, and analyzed by FACS. For WNV infection, were inoculated subcutaneously with 100
PFU of WNV by footpad injection after anesthetization with xylazine and ketamine. The survival
of these animals was monitored over a 22 day time period.

Computational analysis for ChIP-seq and ATAC-Seq
ChIP-seq and ATAC-seq datasets were aligned and mapped on the mouse reference
genome (GRCm38/mm10) using Bowtie software (version 1.1.1) with the following command:–
sam–best -p 4 -m 1 mm10–chunkmbs 1000. Making tag directories was performed by HOMER
(version 4.9) software. Tag directories for ChIP-seq and ATAC-seq were generated by
‘makeTagDirectory’ and duplicated reads in each dataset were discarded using the argument -tbp
1. Browser Extensible Data (BED) files with genomic locations for each specific gene set were
generated using ‘table browser’ tool in the UCSC genome browser web site. The transcriptional
regions (gene body) were extended by 50 kb upstream and downstream using ‘slopBed’ in
BedTools2 software. ChIP-seq or ATAC-seq peaks merged with genomic regions for specific
gene sets were extracted by ‘intersectBed’. Bedgraph files for visualizing as UCSC genome
browser tracks were created by ‘makeUCSCfile’ with following arguments: -fsize 5e7 -res 1
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Single cell ATAC-seq
For library preparation, cells were thawed and then transposed and processed following
the 10X Genomics single cell ATAC kit and protocol as previously described 61. Libraries were
sequenced on an Illumina HiSeq 4000 at the Stanford Functional Genomics Facility. The
generated reads were aligned to the mm10 reference genome assembly using the 10X cellrangeratac count pipeline, yielding aligned, de-duplicated ATAC-seq fragments for each sample and
emulsion barcode. R package `ArchR` was used for all downstream analysis 62. Fragments files
were loaded into ArrowFiles and barcodes containing at least 1000 fragments and having an
enrichment of Tn5 insertions in transcription start sites of at least 4 (relative to +/- 2000 bp from
each TSS) were called as cells.
Data processing steps were performed using the default ArchR workflow 62. Briefly,
dimensionality reduction and clustering were performed on the tile matrix. To capture cell type
specific peaks, peaks were called on each cluster individually and merged into a union peak set.
After determining the union peak set, peaks were annotated by transcription factor motifs.
For track visualization and heat maps, group coverages (pseudobulk) were created for
each sample, each cluster, and each sample within each cluster. These coverages were
normalized such that each coverage had equal fragments in TSS and visualized using the ArchR
Browser62. Marker peaks and marker GeneScores for each cluster were computed using
`getMarkerFeatures` with cutoffs FDR <= 0.01 and Log2FC >= 0.5. All features passing these
cutoffs are shown in the respective heatmaps. Motifs enriched within the marker peaks for each
cluster were computed using `peakAnnoEnrichment` with cutoffs FDR <= 0.1 and Log2FC >=
0.1. The top 8 motifs passing these thresholds for each cluster were visualized in a heatmap.
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Statistics
Statistical analysis for single cell ATAC-sequencing data is described above. Horizontal
lines in figures indicate the mean. Results from independent experiments were pooled as
indicated in figure legends. Data were analyzed using Prism (GraphPad), using unpaired twotailed Student’s t-tests when comparing two groups. *P<0.05, **P<0.01, ***P<0.001,
****P<0.0001.

Data availability
Microarrays are available on the GEO database with the following accession number:
.This data was utilized in Figure 3.5. The sc-ATAC-seq data is available on the GEO database
with the following accession number: . This data is utilized in Figure 3.11 and Figure 3.10.
Following data sets were downloaded and reanalyzed: ChIP-seq data sets for mouse E2-A
(GSE48086), H3K27Ac (GSE63339), NUR77 (GSE102394), for human E2-2 (GSE43876),
ATAC-seq data set for EMP (GSE144243) and Immunological Genome Project (ImmGen) data
sets for ATAC-seq (GSE100738)
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CHAPTER 4:
Discussion and future directions

Parts of this chapter are under review in Immunity. Huang X*, et al. Differential usage of Zeb2
enhancers distinguishes adult and embryonic hematopoiesis. Manuscript under review in
Immunity.
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4.1

Abstract
In this dissertation, we discovered a previously unrecognized TF networks that governs

the differentiation of cDC1 from CDP, the multipotent DC progenitor, that revolves around key
TF Zeb2. Using single-cell RNA sequencing technology, we identified a cluster of cells within
the CDP that expressed transcription factors influencing cDC1 development, such as Nfil3, Id2,
and Zeb2. We determined the functional and regulatory hierarchy of these TFs via genetic
epistasis experiments and established a transcriptional circuit, the resolution of which
corroborate a switch in the regulation of Irf8 expression and determines the fate choices of DCs.
Expanding on this discovery, we generated novel mutant mice and discovered a shared
requirement of the -165-kb Zeb2 enhancer by all adult hematopoietic lineages for Zeb2
expression. Using scATAC-seq and ChIP-seq, we identified a fetal specific +164-kb enhancer
that drives Zeb2 expression during earlier stage of development. These detailed characterizations
of the temporal regulation of Zeb2 and its interaction with other TFs uncovered novel molecular
mechanisms underlying the complex fate choices of multipotent progenitor cells during
hematopoiesis. Additional animal models and genomic analytical tools will be useful in
complementing this study to fully understand molecular mechanisms involving Zeb2.

4.2

The role of Zeb2 in DC1 development
The first part of this dissertation resolves several long-standing puzzles regarding cDC1

development. First, Id2 was proposed to be required for cDC development by excluding pDC
fate potential1,2, but Id2–/– mice lacked only cDC1, and did not show the expected loss of all
cDCs3. Second, cDC1 develop from CDP progenitors that express Irf8 independently of Batf3,
yet later become dependent on Batf3 to maintain Irf8 expression. The basis for this switch from
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Batf3-independent to Batf3-dependent Irf8 expression was unclear. Third, mature cDC1 do not
express E proteins or show +41 kb Irf8 enhancer activity, yet their development requires both.
These apparent inconsistencies all result from a cryptic stage in cDC1 development in which Irf8
expression relies on the E protein-dependent +41 kb Irf8 enhancer. In this study, we examined
this cryptic stage of development to reveal the hierarchy of transcription factors governing cDC1
specification.
Our results define a genetic hierarchy that unifies the actions of the known transcription
factors required for cDC1 development. cDC1s were known to require Irf8, Batf3, Id2, and Nfil3,
but how these factors interacted was unknown. We used Zbtb46-GFP to identify an earlier stage
of cDC1 specification than previously described that occurs within the CDP itself4. scRNA-seq
of the CDP identified clusters of cells defined by the expression patterning of Nfil3, Id2, and
Zeb2. Epistatic analysis revealed a genetic hierarchy in which Nfil3 induces a transition from
CDPs that express high levels of Zeb2 and low levels of Id2 to CDPs that express high levels of
Id2 and low levels of Zeb2. A circuit of mutual repression between Zeb2 and Id2 stabilizes these
distinct states, such that repression of Zeb2 by Nfil3 is required to induce this transition. In
Zeb2hi and Id2lo CDPs, Irf8 expression is maintained by the +41 kb Irf8 enhancer, which is
dependent on E proteins for activity. Upon Id2 induction, E protein activity is lost and Irf8
expression becomes dependent on Batf3 acting at the +32 kb Irf8 enhancer. It is currently unclear
whether Nfil3 directly represses Zeb2 and whether Zeb2 directly represses Id2, as there may be
other factors in this proposed genetic circuit. Nfil3 acts largely as a repressor 5,6, but may
activate transcription in contexts7. Likewise, Zeb2 has been suggested to directly repress Id2
expression8,9, although this has not been rigorously tested. The second part of this dissertation
will expand further on this regulatory network.
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4.3

The regulation of Zeb2 in hematopoiesis
The second part of this dissertation was prompted by our attempt to explain how Id2

suppresses Zeb2 expression during cDC1 development10. cDC1 specification in the CDP is
initiated by a transient pulse of Nfil3 expression that first suppresses Zeb2, which de-represses
Id2 and leads to stable loss of Zeb2, even in the absence of Nfil310. Since ID2 does not bind
DNA, we wondered whether the stable loss of ZEB2 was due to the squelching of positive
regulation at the Zeb2 locus mediated by E-proteins. E2A and E2-2 are both expressed in the
CDP and are inhibited by ID2. Therefore we carried out a functional in vitro test for several
candidate E-protein binding sites in the Zeb2 locus 11 for their role in DC development using in
vitro CRISPR/Cas9 targeting of BM progenitors. This approach identified the -165-kb region as
possibly supporting pDC development, which we confirmed in vivo by generation and analysis
of mice harboring a germline deletion in this region. This region contains a cluster of 4 E-box
motifs, which we confirmed binds to E2A in vitro using EMSA. This Zeb2 enhancer is
necessary for the development of pDCs, B cells, monocytes, and monocyte-derived
macrophages, but not for embryonically derived macrophages and other hematopoietic lineages.
The results of the present study also identify +164-kb Zeb2 enhancer as a cis-element
potentially important for early embryonic hematopoiesis. Vav-cre induced deletion of Zeb2 in
mice results in neonatal lethality that does not occur in Zeb2 –165–/– mice. This indicates that
there are alternative enhancer elements that likely control the expression of Zeb2 in other tissues
such as neurons and melanocytes, and during early hematopoiesis. One such possible enhancer
may be located at -59-kb, where we observed a robust ATAC-seq peak in embryonically derived
MFs. It will be interesting to identify the TFs that are responsible for binding this region, as they
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may be responsible for supporting early embryonic Zeb2 expression. Potential candidates include
MYB, PU.1, and CEBP family members, and testing the role of this enhancer and these factors
in embryonic hematopoiesis will be the basis of future studies.

4.4

Future directions
This dissertation clarified several questions regarding cDC1 development and to a larger

scale, hematopoiesis; it may further reveal a unified lineage diversification mechanism that can
be applied to all hematopoietic lineages.
We identified a cDC1-specified stage that occurs before the development of the precDC1. The cells in this stage express a high level of Irf8, consistent with the high level of Irf8 in
the CDP. Early expression of Irf8 seems to correlate with commitment to the cDC1 lineage, as
shown recently in a report in which Irf8 expression in human hematopoietic stem cells specifies
to the DC1 lineage12. cDC1 specification may occur even earlier than this dissertation suggests,
but may rely on a minimum threshold of Irf8 expression, and not simply early expression in the
BM. The requirement of the +41 kb Irf8 enhancer during the transition from the MDP to the
CDP for subsequent cDC1 specification is consistent with this idea of a minimum threshold for
Irf8 expression. A revised DC development model may require a deeper understanding of the
relationship between Irf8 expression level and activity.
Our results also suggest that cDC1 development may be more closely related to pDC
development than previously appreciated. The actions of the proposed genetic circuit on the +41
kb Irf8 enhancer suggest that Id2 extinguishes E protein activity at the +41 kb Irf8 enhancer and
imposes a requirement for Batf3 at the +32 kb Irf8 enhancer. It is possible that pDCs and cDC1s
share a common progenitor. The emergence of pDCs from myeloid or lymphoid BM progenitors
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is debated, as early studies suggested that pDCs can arise from both lymphoid and myeloid BM
progenitors13. However, two recent studies indicated that late pDC progenitors emerge from the
common lymphoid progenitor and a “pre-pDC” was described14,15. Since these studies did not
perform lineage tracing for prior expression of myeloid markers, such as CD115-Cre, pDCs
progenitors conceivably could emerge in a series of stages that include both myeloid and
lymphoid features, as recently suggested16. Resolving whether pDC and cDC1 share a common
progenitor that has segregated from the cDC2 lineage, or simply share molecular transcriptional
requirements will require additional studies.
Our results also suggest that the +164-kb Zeb2 enhancer is required for Zeb2 expression
in embryonic macrophage progenitors, however, this notion was not rigorously tested. More
genetic models involving the deletion of this enhancer and more specifically the mutation of
certain TF binding motifs will be required to further characterize this cis-element. Furthermore,
this dissertation has examined the temporal regulation of Zeb2 expression, but a detailed
understanding of the regulation of TF expression during development and hematopoiesis might
requireadditional understanding of the spatial aspect. In addition to the ATAC-seq, ChIP-seq and
other genomic analysis performed in this study, characterizing the spatial localization of the Zeb2
locus using either imaging-based methods (DNA FISH), or genomic assays such as 4C or Hi-C
might provide more insight in the spatial and temporal regulation of TF networks.

4.5
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